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Abstract 
Metabolic syndrome is associated with cerebrovascular disease and cognitive impairment. We 
determined vascular reactivity in middle cerebral arteries (MCA), and performed cognitive 
testing using an operant conditioning chamber (OCC) and Morris Water Maze (MWM). Male 
obese Zucker rats (OZR) were used to test the hypothesis that the pro-inflammatory 
environment present in the OZR impairs cerebrovascular tone regulation and is associated with 
neuroinflammation of the white matter and cognitive impairment. Dilation of MCA following 
challenge with acetylcholine was blunted, whereas constrictor responses were enhanced. 
Learning was impaired in the MWM and a shift in swim strategy towards increased allocentric 
navigation was observed. Few impairments were detected in the OCC tests or when white 
matter regions were examined for markers of neuroinflammation. These results suggest that 
the reactivity of MCA in OZR is altered with MetS, and that this impairment is associated with 
cognitive dysfunction in the absence of white matter inflammation. 
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Summary for Lay Audience 
Metabolic syndrome is a cluster of conditions including increased blood pressure, high blood 
sugar, excess body fat around the waist, and abnormal cholesterol or triglycerides. It is a 
prevalent public health concern associated with elevated cardiovascular disease risk 
throughout the body. Impairments associated with this disease are particularly problematic 
when they affect the brain and lead to problems such as stroke (a blockage in an artery that 
supplies blood to the brain). Even in the absence of an acute event such as stroke, metabolic 
syndrome is strongly associated with impaired cognitive function and decreased quality of life. 
The work presented in this thesis aims to describe some of the changes occurring to the ability 
of blood vessels in the brain to alter their diameter which has implications in regulating blood 
flow. It also investigated if these changes are associated with cognitive impairment and 
inflammation in the brain using a rodent model of metabolic syndrome. Understanding these 
risk factors allows for better implementation of targeted therapeutic strategies aimed at 
ameliorating the regulation of blood flow in the brain and has the potential to improve current 
negative outcomes associated with metabolic syndrome. 
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Chapter 1  
1 General Introduction 
This chapter will present a description of the local mechanisms involved in the regulation 
of cerebral vascular tone, their integration with one another, how they can be compromised 
in disease and the resultant functional impairments in cognition. Although impairments to 
the regulation of cerebral vascular tone are not limited to conditions associated with 
metabolic syndrome (MetS) the discussion will focus on the impact of MetS and its 
associated risk factors in contributing to cerebrovascular disease leading to cognitive 
impairment. 
1.1 Overview 
1.1.1 Microcirculation and Homeostasis 
All living cells require a mechanism that allows for the delivery and removal of metabolic 
substrates.  Large organisms have developed cardiovascular systems made up of the heart, 
blood, and network of blood vessels that facilitate this process.  Although each of these 
components is critical to the maintenance of homeostasis the most dynamic changes occur 
at the level of the microcirculation (arterioles, capillaries, venules) by adjusting resistance 
to flow and surface area for diffusion of metabolic substrates in order to maintain 
homeostasis. 
1.1.2 The Cerebral Circulation 
The brain has a high metabolic rate and thus requires a highly disproportional amount of 
blood flow. Although its only 2% of body weight, the brain is supplied by 15-20% of 
cardiac output (Cipolla, 2010), making it one of the most highly perfused organs in the 
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human body. This high metabolic rate coupled with its limited capacity for energy storage 
(Brown & Ransom, 2007) necessitates heavy reliance on oxidative metabolism and thus 
requires constant blood flow to maintain nutrient and oxygen supply, remove waste 
products, and maintain a state of cerebral metabolic homeostasis. Severe under perfusion 
can quickly result in unconsciousness (Van Lieshout et al., 2003) and if prolonged, death 
(Smith et al., 2011); while chronic mild under perfusion is associated with cognitive 
decline (Ng et al., 2016). In addition to its highly regulated and consistent perfusion and 
metabolic rate, the cerebral circulation faces a unique challenge of being enclosed in the 
skull. This rigid structure prevents the volume expansion of tissue and extracellular fluid.  
Swelling within the skull from vasogenic edema, extracellular accumulation of fluid from 
a disruption of the blood-brain barrier (Michinaga & Koyama, 2015), leads to an increase 
in intracranial pressure which in turn can lead to neurologic complications or in more 
extreme cases death (Cipolla, 2010). The unique challenges of the cerebral circulation, 
including intolerance to a restriction of blood flow (ischemia) and edema, coupled with the 
paramount importance of maintaining constant nutrient and oxygen supply to cerebral 
tissue for cognitive processes creates a need for precise regulation of cerebral blood flow 
and therefore, the presence of redundant intrinsic mechanisms for its regulation. The 
anatomy of the brain vasculature ensures multiple routes for blood and oxygen delivery 
potentially allowing for perfusion even in cases of a blocked blood vessel (Gebremedhin 
et al., 2014); however, acute regulation of flow is done primary by altering the diameter of 
blood vessels, and thus the resistance to flow. The major mechanisms of local regulation 
of vascular tone intrinsic to the cerebral vasculature include myogenic, shear, and 
metabolic based regulation. Although each mechanism has a discrete effect on vascular 
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tone the integration of the different contributors to determine an appropriate level of tone 
is much more difficult to discern, especially in the cerebral circulation. These complex 
interactions not only allow for highly accurate control of cerebral blood flow in addition to 
protecting vulnerable downstream capillaries from high pressures and flow rates that could 
otherwise lead to edema, but also introduce several potential areas for failure. The intimate 
interactions of the various mechanisms of regulation of flow mean that the failure of one 
mechanism has the potential to initiate a cascade of events that results in inappropriate 
regulation of flow. As such abnormal execution of vascular tone regulation may form the 
basis of vascular pathologies (El-Yazbi & Abd-Elrahman, 2017). 
1.1.3 Metabolic Syndrome 
MetS is a pathology having a significant vascular component associated with impaired 
cerebral vascular tone regulation. The criteria for a clinical diagnosis of MetS as defined 
by the American Heart Association and National Heart, Lung, and Blood Institute is having 
any three of the following five criteria: elevated waist circumference (men ≥102 cm, 
women ≥88 cm), elevated triglycerides (≥150 mg/dL) reduced HDL cholesterol (men <40 
mg/dL, women <50 mg/dL), elevated blood pressure (≥130/≥85 mmHg), and elevated 
fasting glucose (≥100 mg/dL). With the spreading of Western lifestyle across the globe, 
MetS has become a global problem and is contributing to decreased quality of life and 
increased economic burden (Boutayeb et al., 2013; De Carvalho Vidigal et al., 2013; Fu & 
Prasad, 2014). Thus an understanding of how it alters the cerebral circulation is crucial. 
MetS is categorized by a collection of metabolic risk factors including obesity, 
hypertension, atherogenic dyslipidemia, and impaired glycemic control creating a pro-
oxidant pro-inflammatory environment that raises the risk of developing impaired vascular 
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structures and function (Shin et al., 2013; Donley et al., 2014; Ferdinand et al., 2014; 
DeVallance et al., 2015). These impairments are particularly problematic when they affect 
the cerebral circulation and lead to cerebrovascular pathologies such as stroke or transient 
ischemic attack (TIA) due to the detrimental consequences associated with such events. 
However, cognitive impairments are not limited to individuals that have experienced an 
acute ischemic event since even in their absence MetS is strongly associated with impaired 
cognitive function and decreased quality of life (Rosenberg, 2009; Yates et al., 2012; 
Alfaro et al., 2016; Tsai et al., 2016). Therefore, preventing their occurrence by protecting 
the cerebrovasculature from functional and structural decline is paramount.  
1.2 Cerebrovascular Tone Regulation 
1.2.1 Myogenic Mechanism 
The myogenic mechanism, which was first described by Bayliss, is an intrinsic property of 
the vascular smooth muscle to respond to changes in intravascular pressure which is 
independent of other mechanisms of tone regulation including neural, metabolic, and 
hormonal influences (Bayliss, 1902). The intrinsic nature of the myogenic response is 
supported by its existence in arteries and arterioles that have been sympathetically 
denervated and had their endothelium removed (Schubert et al., 2002) thus leaving only 
the vessel itself to initiate and execute the response. The prototypical response of the 
vascular smooth muscle in response to an increase in intraluminal pressure is initial 
distension quickly followed by a constriction with the opposite occurring in situations of 
decreased intraluminal pressure and tension of the VSMC (Davis & Sikes, 1990). The 
myogenic response has several physiological roles including establishing and maintaining 
basal vascular tone (some degree of constriction) so that resistance may be increased or 
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decreased by vasoconstrictors or vasodilators respectively, in order to regulate tissue 
perfusion. The establishment and maintenance of this partially constricted state in a 
pressurized vessel is referred to as myogenic tone. Additionally, myogenic tone has a role 
in flow and pressure regulation. It functions by constricting to drop the pressure that 
reaches the downstream capillaries and protect them from edema or vascular remodeling 
associated with hypertension in the capillaries (Davis & Hill, 1999; Roman & Dokkum, 
2014). Equally important as protecting from hypertension is the ability of the vasculature 
to promote flow during low pressure by dilating. This ability to alter diameter over a range 
of pressures is referred to as myogenic reactivity. Beyond the local implications for the 
regulation of vascular tone, resistance to flow also has implications for systemic blood 
pressure since mean arterial pressure (MAP) is the product of total peripheral resistance 
and cardiac output. This relationship illustrates the system-wide implications of accurate 
vascular tone regulation. While the myogenic response is present in a variety of vessels 
(arterioles, veins, lymphatic vessels) (Von der Weid, 2013) the aforementioned functions 
of the myogenic response are particularly important in the cerebral circulation due to the 
catastrophic outcomes associated with under or over perfusion including unconsciousness 
and edema respectively. The most prominent myogenic response is found in the cerebral 
circulation with arterioles (resistance vessels) having the most pronounced response 
(Cipolla, 2010). It should also be noted that the large arteries feeding the brain have a 
greater contribution in regulating vascular resistance in the cerebral circulation compared 
to other vascular beds, again providing evidence for the importance of regulating tone in 
the cerebral circulation. A phase model of arterial myogenic behaviour is commonly used 
to describe the response over a range of pressures (Figure 1). In the first phase, there is an 
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initial development of myogenic tone at approximately 40-60 mmHg with increasing 
pressure up to that point causing passive distension.  There is then a phase of myogenic 
reactivity in the pressure range of ~60-140 mmHg. In this range of intralumenal pressure, 
where the myogenic tone has already been established, increases in pressure within this 
range leads to a stretch of VSMC that initiates, a combination of calcium-dependent and -
independent intracellular signaling pathways that leads to cell shortening (Figure 2). 
Finally, there is a phase of forced dilation at transmural pressures greater than 
approximately 140 mmHg (Osol et al., 2002). This process results in a loss of myogenic 
tone, and thus an increase in vessel diameter and a rapid increase in wall tension. Although 
the name implies a degree of passiveness in the process, forced dilation is likely an active 
vasodilation involving potassium channels, nitric oxide (NO), and or reactive oxygen 
species (ROS), which are activated to induced dilation in order to protect the arterial wall 
from damage associated with high intraluminal pressure (Jaggar et al., 2000; Paterno et al., 
2000). For example hydrogen peroxide can induce dilation by hyperpolarizing vascular 
smooth muscle (Sato et al., 2003). If the pressure is reduced to within the myogenic 
reactivity range reestablishment of tone is generally observed. 
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Figure 1: A phase model of cerebral myogenic behaviour. 
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Figure 2: Molecular mechanisms of myogenic reactivity 
Abbreviations: BKCa, large conductance Ca
2+-activated K+ channel; CPI-17, 17-kDa 
protein kinase C-potentiated inhibitory protein; DAG, diacylglycerol; GPCR, G protein-
coupled receptor; IP3, inositol triphosphate; IP3R, inositol triphosphate receptor; MLCK, 
myosin light chain kinase; MLCP, myosin light chain phosphatase; MYPT1, myosin 
phosphate targeting subunit; PIP2, phosphatidylinositol bisphosphate; PKC, protein kinase 
C; PLC, phospholipase C; RyR, ryanodine receptor, SR, sarcoplasmic reticulum; TRPM4, 
transient receptor potential melastatin 4. 
 
1.2.2 Response to Flow (Shear Stress) 
An increase in flow leads to an increase in a frictional force known as shear that is detected 
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by the endothelial cells lining the vessel lumen.  As such, the magnitude of the shear force 
is proportional to blood flow. Shear stimulates physiologically important responses in the 
cerebral vasculature such as encouraging reperfusion after ischemia, aiding in the 
hyperemic response to increased metabolic demand, and perhaps protection of downstream 
capillaries from edema and structural damage. The endothelium which can sense changes 
in shear, has been reported to release constrictor, and dilator factors that act on the adjacent 
layers of vascular smooth muscle cells (VSMC) to produce a level of tone accounting for 
opposing processes (if any). It is generally accepted that in the peripheral circulation flow 
leads to dilation; however, in the cerebral circulation, the response is more controversial 
with both constriction and dilation being reported.  These opposing observations may be 
because of a variety of factors including the area of the brain studied, the preparation used, 
or because of interactions with other mechanisms affecting cerebral vascular tone. Within 
the cerebral circulation, the vertebrobasilar systems appear to elicit flow-mediated dilation, 
as measured in rats and mice (Koller & Toth, 2012) and humans (Fujii et al., 1991). The 
increase in flow is sensed by the endothelium, which initiates a negative feedback 
mechanism in an attempt to decrease the shear stress by dilating. Shear-induced dilation is 
largely endothelium-dependent and is at least partially mediated by nitric oxide (NO) 
(Thorin-Trescases & Bevan, 1998). In endothelial cells, NO is synthesized by the enzyme 
nitric oxide synthase 3 (eNOS) which catalyzes the reaction L-arginine + O2 + NADPH → 
L-citrulline + NO. NO production by the endothelium can also be induced by other stimuli 
other than shear stress, such as acetylcholine (ACh) or bradykinin. Both increase 
endothelial cell intracellular Ca2+ since eNOS is Ca2+-dependent,  and principally activated 
by Ca2+-dependent binding of calmodulin. NO diffuses from endothelial cells to 
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neighboring VSMC where it binds to and activates soluble guanylyl cyclase (sGC), leading 
to increased accumulation of guanosine 3’,5’-cyclic monophosphate (cGMP), which leads 
to relaxation of VSMC (Figure 3). 
 
Figure 3: Endothelial nitric oxide production. 
Abbreviations: ACh, acetylcholine; B2, bradykinin receptor B2; cGMP, cyclic guanosine 
monophosphate; eNOS, nitric oxide synthase 3; GTP, guanosine triphosphate; M, 
muscarinic acetylcholine receptor; NO, nitric oxide; PKG, protein kinase G, sGC, soluble 
guanylate cyclase.  
1.2.3 Flow and Pressure 
In a physiological setting multiple inputs are being processed by the cerebral vasculature 
leading to the generation of a certain level of tone. Pressure and shear stress exerted by 
flowing blood are two mechanical stimuli that have been described to play a major role in 
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the regulation of vascular tone (Burnstock, 1985; Jones et al., 1993). It is, therefore, 
important to consider their interaction when determining the resultant effect on vascular 
tone. At high pressures (approximately >80 mmHg) cerebral vessels tend to constrict in 
response to flow (Reich & Rusinek, 1989; Garcia-Roldan & Bevan, 1990, 1991; de Wit et 
al., 1997). This biphasic response is further supported by findings from Garcia-Roldan and 
Bevan in isolated rabbit pial arterioles that constricted with flow rates from 0 to 20 uL/min 
at 90 mmHg but did not with the same flow at 60 mmHg (Garcia-Roldan & Bevan, 1991).  
1.2.4 Metabolic Control 
The mechanical stimuli of pressure and flow are generally thought to be important in 
setting the basal vascular tone so that metabolic influences are able to cause dilation or 
constriction depending on the needs of the cerebral tissue (Davis & Hill, 1999). Metabolic 
control of vascular resistance is of particular importance in the cerebral circulation since 
cerebral tissue is extremely intolerant to ischemia (Peterson et al., 2011). As such, the 
cerebral circulation has a precise and highly localized coupling between the metabolic 
requirements of cerebral tissue and the magnitude of blood flow by controlling vascular 
resistance. There are numerous vasoactive metabolites that contribute to the control of 
cerebral vascular tone including adenosine, CO2, O2, and adenosine.  Increasing 
concentrations of adenosine, and CO2, along with decreased concentration of O2 result in 
relaxation of VSM and dilation of cerebral resistance vessels. Each metabolite is associated 
with a cascade of events that ultimately either alters intracellular Ca2+ concentration or Ca2+ 
sensitivity of the VSMC and results in a change in vessel diameter. Although the effects of 
each metabolite have been well characterized, the relative importance of each along with 
their interaction with each other and other parameters of tone remains an area of further 
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investigation.  
1.2.4.1 Adenosine 
Adenosine is a naturally occurring nucleoside produced as a byproduct of ATP 
metabolism; thus, its accumulation signals a need for increased blood flow to match the 
metabolic activity. This relationship with metabolism has widely implicated adenosine in 
local regulation of cerebral vascular tone during functional hyperemia, ischemia, or 
whenever the partial pressure of oxygen becomes limited (Berne et al., 1981; Bari et al., 
1998). Adenosine has direct effects on the vasculature (Ramkumar et al., 2001; Tabrizchi 
& Bedi, 2001) that can both vasodilate and hyperpolarize VSMC (Ohta et al., 2013). There 
are four distinct subtypes of adenosine receptors; however, the A2 receptors, a member of 
the G protein-coupled receptor family appears to be of high importance in mediating 
vasodilation (Kusano et al., 2010). Adenosine causes dilation in a concentration-dependent 
manner (Ngai & Winn, 1993) once bound to the A2 receptors (particularly the A2A subtype)  
by activation of adenylate cyclase (Anand-Srivastava et al., 1982) and therefore, cyclic 
adenosine monophosphate (cAMP ) (de Jong et al., 2000) which reduces cytosolic calcium 
and leads to vasodilation. The opening of ATP-sensitive potassium channels (KATP) also 
occurs secondary to the increase in cAMP levels as a result of adenosine binding to its 
receptors on the cell membrane (Li & Puro, 2001). The contribution of opening KATP 
channels to dilation is likely substantial since during blockade of KATP channels with 
glibenclamide, adenosine-induced dilation was reduced by approximately 50% (Carter & 
Kanagy, 2002). Adenosine may also lead to endothelium-dependent dilation since A2A 
receptors located on the endothelium mediate the release of NO. However, the contribution 
of the NO and the endothelium to adenosine-induced dilation is relatively minor, compared 
13 
13 
to ACh-induced dilation for example, since the dose-response curve to adenosine had only 
a relatively small shift to the right after incubation with L-NAME or in the absence of 
endothelium (Prentice & Hourani, 2000). In addition to dilating the cerebral vasculature 
adenosine may also block vasoconstrictive signals in the parenchyma as evidenced by in 
vitro data from Gordon et al. (Gordon et al., 2008). When adenosine receptors were 
blocked with theophylline, dilation was attenuated in response to arterial hypoxia (Morii 
et al., 1987). Similarly, the competitive adenosine receptor antagonist aminophylline 
causes a 20-30% decrease in CBF and cerebral oxygen delivery in normoxia (Willie et al., 
2014b). 
1.2.4.2 Carbon Dioxide 
Similar to adenosine CO2 tends to increase under conditions of increased metabolism 
without adequate flow to eliminate it from the area of production and thus its accumulation 
leads to dilation of the vasculature. High sensitivity to the partial pressure of CO2 (PCO2) 
is unique to the cerebral circulation (Ainslie et al., 2005) causing approximately 3-6% 
increase and 1-3% decrease in flow per mmHg change in arterial PCO2 above or below 
eupnoeic PCO2 respectively.  This high sensitivity is seen throughout the arterial side of 
the vascular network including the large arteries in the neck (Willie et al., 2012) and large 
intracranial arteries (Wilson et al., 2011; Willie et al., 2014a) to the smallest pial arterioles 
and parenchymal vessels (Binks et al., 2008; Mandell et al., 2008; Nöth et al., 2008; 
Piechnik et al., 2008).  
1.2.4.3 Oxygen 
The effects of oxygen are unique in that its availability is required for aerobic metabolism 
rather than being a byproduct of it like some of the metabolic factors discussed. Therefore, 
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it is not surprising that its abundance leads to vasoconstriction and its relative shortage 
leads to dilation. Although its availability is tightly linked to that of PCO2 and H
+ and other 
metabolic byproducts in a physiological setting, studies have been able to discern its 
independent effect in the presence of otherwise constant conditions. There are various 
mediators of hypoxic dilation including endothelial-derived NO (Frisbee et al., 2002a; 
Lynch et al., 2006), prostanoids (Messina et al., 1992; Frisbee et al., 2002a), 20-HETE 
(Frisbee et al., 2002a) and EDHF (Liu & Flavahan, 1997); however, the contribution of 
each factor appears to be dependent on the severity of hypoxia (Frisbee et al., 2002a). In 
all cases, there appears to be significant involvement by the endothelium to mediate the 
dilation, which is further supported by a reduction in hypoxic dilation when isolated vessels 
were exposed to indomethacin, an inhibitor of arachidonic acid (AA) metabolism, and thus 
the production of prostacyclin (PGI2) (Busse et al., 1983, 1984; Halvorson et al., 2019) and 
to a lesser degree by L-NAME (an inhibitor of NO production from NOS) (Halvorson et 
al., 2019). Therefore, PGI2 is likely a substantial contributor to hypoxic dilation with a 
lesser but likely still significant role for NO.  
1.3 Effects of Metabolic Syndrome 
1.3.1 Cerebrovascular Tone Regulation with Metabolic Syndrome 
Each component implicated in the regulation of tone has a multitude of signals being 
produced that are intended to alter the vasomotor response from the VSMC. Signals from 
myogenic, shear, metabolic, and neurovascular influences may be additive or opposing in 
their effect on VSMC and further combine with one another creating intricate and precise 
regulation of cerebral vascular tone. This complexity also introduces many possible steps 
in the pathway for an abnormal response to occur. Accordingly, changes to the regulation 
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of tone may form the basis of several pathologies. MetS and its contributing risk factors 
tend to alter the regulation of cerebral vascular tone by inducing changes in both the 
structure and function of the vessels. These risk factors include hypertension, type 2 
diabetes mellitus (T2DM), and obesity which promote a pro-inflammatory pro-oxidant 
state. Functionally, MetS is associated with increased smooth muscle activation and 
endothelial dysfunction which has important implications for the ability of a vessel to dilate 
in response to a multitude of stimuli previously discussed including hypotension, shear, 
hypoxia, and other metabolic stimuli. Increased myogenic properties are consistently 
overserved in MetS in multiple vascular beds (Frisbee et al., 2002b; Hayashi et al., 2002) 
including in the cerebral circulation (Phillips et al., 2005; Jarajapu et al., 2008; Brooks et 
al., 2015). This increase in constriction may be due to both a decrease in buffering capacity 
from endothelial dysfunction and alterations in the vascular smooth muscle itself 
(Baumbach et al., 1994; Brooks et al., 2015). The chronic inflammatory state seen in MetS 
likely contributes to the reduction in NO bioavailability due to increased scavenging to the 
produced NO by reactive oxygen species (ROS) converting the NO to peroxynitrate before 
the NO may induce dilation (Kazuyama et al., 2009). Other theories suggest an uncoupling 
of the enzymatic reaction, converting eNOS into a superoxide producing enzyme, which 
leads to less NO production (Li & Förstermann, 2013). Reduced NO bioavailability is 
consistently reported to evolve in parallel with oxidant stress and the development of a 
chronic inflammatory state (Barbato et al., 2005; Dandona et al., 2005). This is supported 
by improved dilation of the middle cerebral artery (MCA) with the pretreatment of the cell-
permeable superoxide dismutase mimetic TEMPOL in a model of T2DM (Halvorson et 
al., 2019). Interestingly some studies have actually shown an increase in eNOS expression 
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which may be an attempt to compensate for the increased scavenging; however, they too 
continue to find reduced dilator reactivity (Kazuyama et al., 2009).  
Aside from reduced NO bioavailability, a shift in arachidonic acid metabolism (AA) 
towards the production of constrictors and away from dilators that are highly responsible 
for hypoxic dilation has been demonstrated in a previous study (Halvorson et al., 2019). 
PGI2 and TxA2 are two notable opposing vasoactive end products of AA metabolism, 
causing vasodilation and vasoconstriction respectively whose production is altered in 
MetS. The cascade of AA metabolism is described in further detail in the following figure 
(Figure 4). A change in sensitivity to various metabolites in addition to their differential 
production may contribute to impaired vasomotor responses. For example, in studies using 
sodium nitroprusside (SNP), an exogenous NO donor, while blocking endogenous NO 
production by eNOS using L-NAME, found less relaxation of the MCA in spontaneously 
hypertensive rats which was attributed to a decreased expression of sGC (López-Farré et 
al., 2002; González et al., 2008). In a model of T2DM decreased sensitivity of MCA to the 
PGI2 analog iloprost was also found suggesting that decrease sensitivity (and production 
as mention previously) of dilators may be contributing to the impaired dilation of the 
cerebral circulation in MetS (Halvorson et al., 2019).  
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Figure 4: Arachidonic acid metabolism cascade. 
Abbreviations: COX-1, cyclooxygenase-1; COX-2, cyclooxygenase-2; PGE2, 
prostaglandin E2; PGF2, prostaglandin F2alpha; PGI2, prostacyclin; TxA2, thromboxane 
A2. 
 
Impaired dilation in response to exogenous dilator metabolites may also be due to vascular 
remodeling. Structural changes are an important consideration since even if the smooth 
muscle of a cerebral vessel is able to relax due to metabolic influences resulting in 
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hyperpolarization, remodeling may prevent an increase in lumen diameter which is 
ultimately the major contributor to acute changes in resistance and thus the regulator of 
flow. Hypertension is largely implicated in the thickening of the vascular smooth muscle 
as well as increasing the ratio of collagen to elastin in the vessel which increases its 
stiffness. High intralumenal pressure increases the shear stress exerted on the vascular 
endothelium which normally could be restored to baseline by NO-induced vasodilation; 
however, in a disease state with impaired NO production, there is a reduced ability to dilate 
resulting in endothelial damage and upregulation of atherogenic genes (Humphrey, 2008; 
Davies, 2009). As a means of protection from chronically increased shear stress and wall 
tension that may lead to downstream edema cerebral vessels tend to hypertrophy with 
chronic hypertension, but this protective hypertrophy is also detrimental (Cipolla et al., 
2018). Since wall tension is equal to the product of intraluminal pressure and radius, and 
wall stress is the quotient of wall tension and wall thickness, hypertension-induced 
hypertrophy and inward remodeling resulting in a decrease in radius and increase wall 
thickness can normalize both the wall tension and wall stress (Cipolla et al., 2018). 
Although this remodeling may be protective in regard to increases in pressures and 
protecting the downstream capillaries from edema it increases the cerebrovascular 
resistance and limits the dilation reserve during hypotension and therefore, presents itself 
as a right-shift in the autoregulatory range (Heistad & Baumbach, 1992; Iadecola & 
Davisson, 2008). The development of myogenic tone at higher pressure implies an 
increased lower limit of autoregulation. This predisposes cerebral tissue to reduced blood 
flow during hypotension. When pressure drops below the lower limit flow becomes 
dependent on the passive diameter of the vessel.  Not only does an impaired lower limit 
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predispose hypertensive individuals to ischemia but the reduced passive diameter from 
vascular remodeling further compromises flow to cerebral tissue resulting in hypoxic areas 
(Pires et al., 2013).  
In addition to hypertrophy and inward remodeling, there is substantial arterial stiffening 
commonly seen in MetS.  Arterial stiffening is a natural process of aging; however, many 
of the cardiovascular risk factors involved in MetS have individually and synergistically 
been shown to expedite this process. Stiffening vessels favor both increased blood pressure 
and increased blood flow pulsations to reach further down the vascular network into the 
microcirculation of peripheral organs including the brain (Chantler & Larkin, 2020). The 
pro-oxidant stress of ROS may interact with components of the perivascular matrix and 
initiate collagen cross-linking and deposition as well as the breakdown of elastin making 
the vessel less distensible (Chantler & Frisbee, 2015). This is measured by a left shift in 
the stress-strain curve of isolated cerebral vessels under passive conditions achieved by 
using a Ca2+-free solution preventing the development of tone (Brooks et al., 2015). The 
stiffening vessels from increased collagen to elastin ratio is made worse by the thickening 
of vessel walls previously discussed. In a model of T2DM with hypertension significant 
collagen deposition in addition to medial hypertrophy, increasing the wall the lumen ratio 
and stiffness of the rats MCA, (Harris et al., 2005) was demonstrated while T2DM in the 
absence of hypertension does not appear to induce structural changes to the cerebral 
vasculature (Halvorson et al., 2019). This along with data that suggest the increase in 
arterial stiffness seems to follow a time course similar to that of the onset of hypertension 
suggests a strong relationship between hypertension and vascular remodeling (Payne et al., 
2010). Chronic uncontrolled hyperglycemia and inflammation do tend to lead to the 
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development of hypertension and thus contribute to changes in the composition of cerebral 
vessels and it is likely the combination of both, as seen in MetS, that increases the degree 
to which remodeling occurs.  
1.3.2 Cognitive Impairment Associated with Metabolic Syndrome  
With these impairments to cerebrovascular tone regulation and thus blood flow regulation 
the brain becomes susceptible to ischemia leading to tissue damage, inflammation and 
cognitive impairment. However, cognitive impairments are not limited to individuals that 
have experienced an acute ischemic event. Since even in their absence both 
epidemiological and clinical studies strongly suggest the presence of an interaction 
between MetS and cognitive impairment  (Rosenberg, 2009; Yates et al., 2012; Alfaro et 
al., 2016; Tsai et al., 2016). Vascular cognitive impairment (VCI) is a term used to describe 
cognitive impairment that is caused or associated with vascular factors (Hachinski et al., 
2006). One brain structure that may be particularly susceptible to chronic mild under 
perfusion is the white matter, which are areas of the central nervous system that are mainly 
made up of myelinated axons. White matter has the general role of transferring information 
within neural networks (Filley, 2005) by acting as a relay mechanism in coordinating 
communication between the different brain regions. Therefore, the preservation of its 
structure is essential for cognitive processes.  White matter forms the majority of the deep 
brain and because of this anatomical positioning along with its precarious blood supply 
from terminal arterioles that have limited anastomosis and collateralization it is particularly 
vulnerable to dysfunction or occlusion of the vasculature associated with MetS leading to 
white matter damage and neuroinflammation (Iadecola & Gottesman, 2019). As such white 
matter inflammation is an event associated with both cognitive decline and MetS which 
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has been suggested to be one of the shared mechanisms contributing to the association of 
these two conditions (Misiak et al., 2012). Although microglia are not the only cell type 
responsible for the inflammatory response in the brain, their activation is a strong indicator 
of a proinflammatory environment (Harry & Kraft, 2008) and reducing their activation has 
been shown to improve white matter function in a model of cerebral vascular disease 
(Manso et al., 2018). Therefore, their activation will be used as an outcome measure of 
neuroinflammation with particular attention being paid to microglia activation in white 
matter. Activation of astrocytes in inflammatory environments may also promote the 
growth and activation of microglia (Von Bernhardi & Eugenín, 2004) and is used as a 
secondary measure of neuroinflammation in this thesis. VCI can affect all cognitive 
domains; however, the susceptibility of the white matter to vascular dysfunction and its 
importance with executive function means VCI frequently results in executive dysfunction 
(Smith, 2017). Executive function encompasses the cognitive domain that enables 
functional independence. These subdomains include inhibitory control such as ignoring 
stimuli that is not associated with goal-directed behaviour, working memory (holding and 
manipulating information that is not perceptually present)  and cognitive flexibility (the 
ability to change goals) (Diamond, 2013).  Many individuals with MetS may be diagnosed 
with understated deficits of VCI including cognitive slowing, inattention, and executive 
dysfunction (Kozora & Filley, 2011). Much of the changes to behaviour in rodent models 
of MetS has focused on hippocampal dependent cognitive impairments such as memory 
and spatial learning (Winocur & Gagnon, 1998) and the resultant hippocampal 
neuroinflammation (Gomez-Smith et al., 2016) with limited investigation into examining 
particular subdomains of executive function. Therefore, the implementation of a rodent 
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model of MetS known to exhibit cerebrovascular dysfunction is needed to investigate these 
subdomains of executive function and their association with white matter inflammation. 
1.3.3 The Obese Zucker Rat as a Model of Metabolic Syndrome 
The obese Zucker rat (OZR) provides an appropriate model for the study of MetS based on 
the recessive dysfunctional leptin receptor gene mutation leads to an impaired satiety 
reflex, and thus a chronic elevation in food intake (Bray, 1977; Kurtz et al., 1989). This 
leads to the rapid development of extensive obesity characterized by both hypertrophy and 
hyperplasia of adipocytes and the development of associated disease states including 
insulin resistance and hypertriglyceridemia (Bray, 1977). Additionally, OZR develops 
clinically relevant hypertension best characterized as mild to moderate (Toblli et al., 2004; 
Frisbee, 2005; Johnson et al., 2006)  as well as a pro-inflammatory pro-thrombotic 
environment (Vaziri et al., 2005). The parallel development of metabolic risk factors to 
clinically relevant degrees coupled with the prolonged period of hypertriglyceridemia and 
insulin resistance prior to overt T2DM supports the use of OZR as an appropriate model 
for studying the origin, outcomes, and potential treatment for MetS in humans. The OZR 
has demonstrated both depressive and anxious behaviour (Brooks et al., 2018b) but little 
work has been done using more comprehensive tests to investigate executive dysfunction 
that could be related to impaired cerebrovascular tone regulation and white matter 
pathology. Therefore, gaining an understanding of the cognitive deficits potentially 
brought on by impairments in vascular tone regulation in a model of MetS is of interest. 
1.4 Summary 
In summary, the regulation of vascular tone involves a complex set of pathways with 
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myogenic, shear, and metabolic control. The mechanical influences of pressure and flow 
serve as a stimulus for the myogenic and shear responses to set a basal level of tone over a 
wide range so that metabolic factors have room to produce vasoactive responses on the 
vasculature. Due to the paramount importance of precise cerebral blood flow control these 
mechanisms are particularly pronounced and redundant in the cerebral circulation allowing 
for greater protection against insufficient perfusion or edema and capillary damage in 
situations of hypotension and hypertension respectively. However, due to the complexity 
of these homeostatic blood flow mechanisms there is the potential for the development of 
a pathological state. MetS presents a constellation of cardiovascular risk factors that are 
highly linked to the development of such cerebrovascular pathologies increasing the risk 
of stroke, TIA, and vascular dementia. The metabolic and inflammatory changes in MetS, 
such as increased oxygen stress and the pro-inflammatory state likely contribute to a shift 
in cerebral vascular tone regulation towards a constricted state. This occurs through 
mechanisms including vascular remodeling, which decreases the lumen size and increases 
stiffness, and when paired with endothelial dysfunction and increased activation of the 
vascular smooth muscle it promotes increased cerebrovascular resistance. This right shift 
to the autoregulatory zone of myogenic regulation allows for enhanced protection from 
hypertension but leaves cerebral tissue, the white matter in particular, vulnerable to under-
perfusion and the development of neuroinflammation.  
1.5 Hypothesis 
The pro-inflammatory and high oxidative stress environment present in the OZR will alter 
vascular reactivity through mechanisms related to endothelial cell dysfunction. These 
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changes will present in conjunction with markers of white matter inflammation and 
evidence of executive dysfunction. 
1.6 Specific Aims 
1. To determine whether alterations to the structure and function of small resistance 
vessels including myogenic tone regulation, endothelial function, or wall 
mechanics exist in a model of metabolic syndrome and to determine the 
mechanistic contributors to changes in this response between the OZR and control 
lean Zucker rat (LZR). These experiments employ pressure myography of the 
middle cerebral artery with specific mechanical and pharmacological challenges to 
determine vasomotor diameter and mechanical responses in MetS. Pressure 
myography allows for precise measurement of the vasomotor responses in a 
controlled environment under near physiological conditions while being able to 
easily manipulate variables including intralumenal pressure, and agonist 
concentration. Information into the mechanistic changes occurring in Mets was 
achieved by probing of dozens of genes related to endothelial cell biology 
simultaneously by using a PCR array to provide an efficient workflow into the 
up/down regulation of endothelial genes in MetS. 
2. Determine if the impairments in cerebrovascular regulation present in conjunction 
with impaired cognition. These experiments involved the use of two established 
cognitive tests: an operant-chamber-based test of extradimensional set 
shifting (Brady and Floresco, 2015)  and the Morris water maze (MWM) which 
allows for examination of subdomains of executive functioning previously linked 
to white matter inflammation and allows for comparison of previous findings 
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related to hippocampal dependent function by testing spatial learning, memory, and 
working memory. 
3. To determine if the impairments associated with metabolic syndrome are associated 
with markers of neuroinflammation. These experiments use immunohistochemistry 
to visualize key cellular components of the inflammatory response, microglia and 
astrocytes, in the white matter areas of the brain and the hippocampus. Activated 
microglia were identified by OX6 primary antibody for major histocompatibility 
complex II (MHCII) and glial fibrillary acidic protein (GFAP) primary antibody 
was used to identify reactive astrocytes. 
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Chapter 2  
2 Materials and Methods 
2.1 Vascular Reactivity 
2.1.1 Animals 
Male lean Zucker rats (LZR) and obese Zucker rats (OZR) (Harlan/Envigo) were purchased 
at ~10 weeks of age and were maintained on standard chow and tap water ad libitum until the 
time of final usage.  Animals were housed in the animal care facility at the Schulich School 
of Medicine and Dentistry at the University of Western Ontario and all protocols received 
prior Institutional Animal Care and Use Committee approval (Appendix 5). 
2.1.2 Experimental Design 
At ~18 weeks of age, each rat was weighed, anesthetized with injections of sodium 
pentobarbital (50 mg•kg-1 i.p.) and received tracheal intubation to facilitate the maintenance 
of a patent airway.  A carotid artery and an external jugular vein were cannulated for 
determination of arterial pressure using the BP-1 pressure monitor (World Precision 
Instruments Inc., Sarasota, FL) and for infusion of additional anesthetic, respectively, as 
necessary. Blood glucose was taken using a Contour glucose meter (Bayer, Toronto, ON) on 
blood collected from a tail vein prick. While deeply anesthetized, each rat was euthanized 
by decapitation, after which the brain was removed from the skull case and placed in cold 
physiological salt solution (PSS; 4ºC). Subsequently, MCA were dissected from their 
origin at the Circle of Willis. Each MCA was doubly cannulated with glass micropipettes 
(100-125 𝜇𝑚 tip diameter) in a heated chamber (37C) that allowed the lumen and exterior 
of the vessel to be perfused and superfused, respectively, with PSS  (pH 7.4) from separate 
reservoirs (Living Systems Inc., Burlington, MA). The PSS had the following composition 
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(mM): 130 NaCl, 4 KCl, 1.2 MgSO4, 4 NaHCO3, 1.8 CaCl2, 1.8 HEPES, 1.18 KH2PO4, 
0.03 EDTA, and 6 glucose. Any side branches were ligated using a single strand teased 
from 6-0 suture. Vessel diameter was measured using television microscopy and an on-
screen video micrometer (Butcher et al., 2012). 
2.1.3 Measurements of Vascular Reactivity in Ex Vivo Middle 
Cerebral Arteries 
Following cannulation, MCAs were extended to their in situ length and equilibrated at 80% 
of the animal's mean arterial pressure (MAP) to approximate in vivo perfusion pressure 
(Lombard et al., 1999). Any vessel that did not demonstrate significant active tone at the 
equilibration pressure was discarded. Active tone at the equilibration pressure was 
calculated as (∆D/Dmax)•100, where ∆D is the diameter increase from rest in response to 
Ca2+-free PSS, and Dmax is the maximum diameter measured at the equilibration pressure 
in Ca2+-free PSS. The active tone for vessels in the present study averaged 33.1% in LZR 
and 39.2% in OZR. Following equilibration, the myogenic activation was assessed in MCA 
over the range of 5, 20-160 mmHg, in 20 mmHg increments. Pressure was changed non-
sequentially, and vessels were allowed 5 minutes to equilibrate at each pressure before 
arterial inner and outer diameters were recorded.  Within each vessel, vascular reactivity 
curves were determined in response to increasing bath concentrations of acetylcholine 
(ACh) (10-10 M–10-6 M), 5-hydroxytryptamine (5-HT) (10-10 M–10-6 M), or adenosine (10-
8 M–10-4 M).  Agonists were added directly to the 10 mL bath surrounding the MCA and 
were allowed 5 minutes to equilibrate. Additionally, myogenic activation was repeatedly 
assessed over the same range of pressures (5, 20-160 mmHg) with a concentration of 
agonist 10-6 M bath concentration for acetylcholine and 5-HT, and 10-4 M for adenosine.  
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2.1.4 Data and Statistical Analysis 
Mechanical responses following challenge with logarithmically increasing dosages of 
acetylcholine or adenosine were fit with the three-parameter sigmoidal equation:  
𝑦 =
𝑎
1 + 𝑒−(
𝑥−𝑥0
𝑏
)
 
where y represents the vessel diameter and x is the agonist concentration. As a result of this 
approach, the upper bound represents that statistically determined asymptote for the 
concentration-response relationship and does not assume that the vascular response at the 
highest utilized concentration of the agonist represents the maximum possible response.  
Rather, the sigmodal relationship of best fit to the data will predict the statistical upper 
bound of the response given the data points entered into the model. As such, the upper 
bound is frequently slightly different than the dilator response of the vessel at the highest 
concentration of the agonist. Mechanical responses following challenge with logarithmically 
increasing dosages of 5-HT were analyzed by a repeated measure ANOVA since the 
sigmoidal equation did not fit the response. The myogenic properties of MCA from each 
experimental group was plotted as mean diameter at each intraluminal pressure from 60 to 
140 mmHg as this is frequently regarded as the myogenic reactivity range (Osol et al., 
2002; Butcher et al., 2013) and fitted with a linear regression 
𝑦 = 𝛼0 + 𝛽𝑥 
where the slope coefficient β represents the degree of myogenic activation (∆diameter/ 
∆pressure). Increasingly negative values of β therefore, represent a greater degree of 
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myogenic activation in response to changes in intralumenal pressure.  Data fitting was 
performed using Sigma Plot, version 13.0 (Systat Software Inc.), and statistical analysis 
were performed using SPSS, version 26 (IBM). All data are presented as mean ± SEM. 
Differences in all slope coefficients or descriptive characteristics between LZR and OZR 
groups were assessed using the Welch’s t-test (two-tailed) for comparison of means of 2 
groups and multiplicity of comparisons was corrected using the Holm-Sidak method. A 
repeated measured mixed analysis of variance (ANOVA) was used to determine the effect of 
group, agonist, and group-agonist interaction followed by Sidak’s post hoc tests. In all cases, 
P<0.05 was taken to reflect statistical significance. 
2.2 PCR Array 
Immediately following dissection of the MCA 6 LZR and 6 OZR brains from 18 weeks old 
rats were flash-frozen on a metal bar over dry ice. RNA was extracted with a monophasic 
solution of TRIzol (Invitrogen, Carlsbad Calif) following the manufacturer’s instructions. 
Chloroform was added and each sample was separated into three phases (top aqueous phase 
solution containing RNA, and middle interphase and lower organic phase containing 
excess lipid, DNA and protein). The RNA was collected from the aqueous upper phase and 
isolated after incubation with isopropanol, washed in ethanol and resuspended in RNAse 
free water. The quality and quantity of the RNA were quantified by optical density ratio at 
260-280 nm using a Nanodrop. 1 g of RNA was used to synthesize cDNA following the 
RT2 First Strand Kit (SA Biosciences, Hilden, Germany). Quantitative real-time PCR 
(qPCR) reactions were performed in 25L of final volume with RT2 SYBR Green ROX 
qPCR Mastermixes in a QuantStudio™ 3 Real-Time PCR system (Applied biosystems, 
Foster City, Calif). The amplification protocol included: 95 C for 10 min and 40 cycles of 
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95 C for 15 s and 60 C for 1 min. Gene expression profiles were then generated with 96-
well arrays containing endothelial-related genes (PAHS; 084, SA Biosciences) using the 
rat endothelial cell biology RT2 profilerTM PCR array (SA biosciences) containing 84 
endothelial-related genes in accordance with the manufacturer’s instructions. Data were 
analyzed with the RT2 Profiler software (version 3.4; SA Biosciences). The relative gene 
expression was normalized with multiple control genes and the fold change in gene 
expression within OZR samples compared with the control LZR samples. Genes that had 
undergone significant upregulation or downregulation were identified. Data are presented 
as means  SD for the number of samples (n=4 per group). qPCR primers for significantly 
up/down-regulated genes were then designed and optimized for validation of the PCR array 
results with n=6 rats per group. The amplification specificity was verified by an analysis 
of the melting curves. To quantify gene expression, the comparative Ct method (2-Ct) was 
applied. The student t-test was applied for comparison of means of 2 groups. 
2.3 Cognitive Testing 
2.3.1 Animals 
A separate cohort of Male LZR and OZR (Harlan/Envigo) (n=8 per group) were purchased 
at ~10 weeks of age and were maintained on standard chow and tap water ad libitum until 16 
weeks of age, to allow for testing to be completed by 18 weeks of age and coincide with the 
age of animals used for vascular reactivity and qPCR experiments.   
2.3.2 Set Shift and Reversal 
At 16 weeks of age they began the set shifting protocol, which included side bias 
determination (Levit et al., 2017). Rats were fasted overnight and maintained on food 
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restriction for the duration of the set shifting protocol in order to ensure motivation for 45 
mg sucrose pellets (Dustless precision pellets, Bio-Serv) as behavioural reinforcement in 
the sound-attenuated operant conditioning chamber, cleaned with 70% ethanol (Med 
Associates). Correct lever presses were reinforced with the sucrose pellets using a fixed-
ratio 1 schedule. After habituation to the chamber rats began lever- pressing training where 
they were required to lever press on at least 85 of 90 trials of alternating sides lever 
presentations before progressing to visual cue discrimination. 24 h after initial training, rats 
were trained on visual cue discrimination which involved both levers extending with only 
one lever paired with the light cue for 100 trials pseudorandomly alternating sides. Pressing 
the lever associated with the light cue was a correct response and a sucrose pellet reward 
was given (Figure 5A). A passing criterion of 8 correct consecutive responses was used for 
completion. 24 h later a retrieval session of 20 trials was performed to evaluate retention 
of the visual cue discrimination task immediately followed by 120 trials of response 
discrimination termed set shift. In this task only one lever (either left or right whichever 
was opposite to a previously determined side bias) would yield a food reward, even though 
the light continued to illuminate on alternating sides (Figure 5B). The passing criterion for 
response discrimination was also 8 correct consecutive responses. Again a 24 h delayed 
20-trial retrieval test was given for response discrimination immediately followed by a 120-
trial reversal session. In this task, the opposite lever yielded a reward and again the cue 
light continued to pseudorandomly alternate during the reversal trials (Figure 5C). During 
all tasks (visual cue, response, reversal), a 10 s response period was used during which the 
chamber was illuminated. If the correct lever was pressed, the chamber remained 
illuminated for 4 s so that rats could retrieve the sucrose pellet reward. This was followed 
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by a dark inter-trial period making the entire single-trial last 30 s. Cue lights were presented 
3 s before lever extension and extinguished upon lever press or the end of the 10 s response 
period.  
 
Figure 5: Operant conditioning chamber tasks 
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2.3.3 Morris Water Maze 
 One week following set shifting rats were tested in the MWM. A 144 cm diameter water 
tank filled with room temperature water dyed black with non-toxic acrylic paint was used 
in a dimly lit room. A target platform of 12 cm diameter was submerged 3 cm below the 
water surface. Rats were placed in the water from a fixed starting position and were given 
90 s to locate the hidden platform in order to be removed from the water tank. Six learning 
trials were performed 1 h apart as has been previously adapted from a MWM protocol 
(Levit et al., 2019). 24 h after the learning trials the rats were placed in the water tank with 
no platform and their swim path was recorded. In addition to tracking the rat’s location 
over time, swim strategies were analyzed according to swim time in different set regions 
(Figure 6). Swim time in the annulus, a 27 cm wide ring, was used to represent the use of 
egocentric navigation based on distance from the wall (Rogers et al., 2017). This egocentric 
navigation (navigating by internal cues) (Vorhees & Williams, 2014) was also measured 
in the annulus outside of the target quadrant in order to determine if this egocentric strategy 
was used in the rest of the maze and not merely in the target quadrant. Thigmotactic 
behaviour (motion in response to touch stimuli) was represented by time in the thigmotactic 
region defined as a 10 cm wide ring along the perimeter of the water maze. Finally, 
allocentric navigation (characterized by navigation using distal cues) (Vorhees & 
Williams, 2014) was approximated by a subjective measure of the time that the rat was 
directed at the platform location (Rogers et al., 2017). After the probe tests, potentially 
confounding differences in visual perception or swim speed, perhaps due to body weight 
differences, were evaluated on 4 cued trials wherein the location of the platform was visibly 
marked. All swim paths were tracked using ANYmaze tracking software, version 6.33 
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(Stoelting Company), with a top-view webcam (C525, Logitech). The experimenter was 
not visible to the rats during testing.  
 
Figure 6: Areas used to approximate swim strategies during the 90 s probe test 
Morris Water Maze. 
2.4 Immunohistochemistry and Image Processing 
After all behavioural testing was complete, rats were euthanized by intraperitoneal injection 
of sodium pentobarbital. Rats (n=6 per group) were subsequently perfused transcardially with 
200 mL of 0.01 M phosphate buffer saline followed by 200 mL of 4% paraformaldehyde 
(PFA). Once perfused the brains were removed from the skull and placed in 4% PFA for 24 
h then transferred into a 30% sucrose solution until saturated. 35 μm coronal sections were 
prepared using a cryostat (CryoStar NX50, Thermo Fischer Scientific) and stored in 
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cryoprotectant at -20 °C until all tissue was available for immunohistochemistry (IHC). 
Standard protocols were followed for DAB-mediated IHC of free-floating sections, using 
an ABC-HRP kit (Thermo Fischer Scientific #32020).  A 1:1000 concentration of OX6 
primary antibody for MHC II was used to identify activated microglia (Lue et al., 2010) 
(BD Pharmingen #554926), along with a 1:2000 concentration of GFAP primary antibody 
to identify the number of astrocytes indicative of reactive astrocytes  (Sofroniew & Vinters, 
2010) (Sigma-Aldrich #G3893). Stained brain sections were mounted onto slides and 
allowed to air-dry overnight. They were then dehydrated in baths of progressive 
concentrations of ethanol and xylene, and finally cover-slipped with DePex mounting 
medium (BDH Chemicals). 
A 10x objective lens on an upright microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour 
camera, NIS Elements Imaging) was used to create stitched micrographs of coronal 
sections. Prior to each scan, white balance was automated using an off-tissue reference 
point and a focus plane was programmed for the micrograph. For all images, the light 
source intensity, exposure, aperture, and diaphragm parameters were fixed. Anatomical 
regions of interest (cingulum, corpus callosum, internal capsule, hippocampus) were 
captured at the coronal sections of Bregma +2.00 mm, +0.00 mm, −3.00 mm, and −5.50 
mm with each rat having a single section analyzed at each of the coronal planes. The subset 
of the corpus callosum, the supraventricular corpus callosum (SVCC), was outlined on the 
anterior two coronal planes of the corpus callosum, which excluded the portion of the 
corpus callosum that was medial to the lateral ventricles. Micrographs were processed and 
analyzed using ImageJ (version 1.53) where regions of interest were outlined using the 
polygon tool. Images were then converted to 8-bit, processed using the subtract background 
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command, and thresholded with a fixed grayscale cut-off value of 237. Area coverage (%) 
was recorded for each region of interest and used for statistical analysis using a repeated 
measures mixed ANOVA. For anatomical regions that spanned multiple coronal sections 
(corpus callosum, cingulum, hippocampus), a weighted average area coverage was 
calculated. 
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3 Results 
3.1 Baseline Characteristics 
Table 1 presents body mass, MAP, and blood glucose, for both the OZR and LZR control 
at ~18 wk of age. The OZR exhibited characteristics of MetS compared to the age matched 
LZR control including obesity, hypertension and insulin resistance.  
 
LZR OZR 
Mass, g 414 ± 7 645 ± 14* 
MAP, mmHg 106 ± 1 126 ± 1* 
Glucose, mmol/L 7.6 ± 0.3 12.1 ± 0.5* 
Table 1: Baseline characteristics 
Values are means ± SEM; All animals were male ~18 wk of age (n = 21 per group). Mean 
arterial pressure (MAP) was measured at the carotid artery while under anesthesia with 
sodium pentobarbital. Glucose was measured from a drop of blood collected from the tail 
vein. *P< 0.05 vs LZR using Welch’s t-test. 
3.2 Responses from Ex Vivo Middle Cerebral Arteries  
Dilator responses of ex vivo MCA from OZR were impaired compared to LZR in response 
to challenge with increasing concentrations of ACh (Figure 7A) but not adenosine (Figure 
7B). The constrictor responses of isolated MCA in OZR were enhanced compared to LZR 
as measured by the response to increasing concentrations of 5-HT (Fig 8A) and by 
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myogenic activation with increasing intraluminal pressure (Fig 8B). Responses of ex vivo 
MCA for both slope of myogenic activation and average lumen diameter from LZR and 
OZR in response to increased intraluminal pressure and concentration of agonists, ACh 
(10-6 M) (Figure 9A), adenosine (10-4 M) (Figure 9B), and 5-HT (10-6 M) (Figure 9C) were 
determined across the intraluminal pressure range 60-140 mm. Pre-treatment with either 
ACh or adenosine increased the slope of myogenic activation and average arteriolar 
diameter.  While 5-HT significantly decreased arteriolar diameter. The effect of group 
(LZR vs OZR) was not significant in the response to ACh and pressure but was in response 
to either adenosine or 5-HT and pressure. No difference in group by agonist interaction 
was observed. To determine whether there was evidence of remodeling in OZR the 
mechanical characteristics of ex vivo MCA under Ca2+-free, passive conditions in response 
to increasing intraluminal pressure were determined. The inner diameter of the MCA 
(Figure 10A) and incremental distensibility (Figure 10B) of the MCA were not different 
between LZR and OZR at any level of intraluminal pressure. 
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Figure 7: Dilation of ex vivo middle cerebral arteries 
The dilation of isolated middle cerebral arteries at 80% mean arterial pressure from lean 
Zucker rat (LZR) and obese Zucker rat (OZR) in response to increasing bath concentrations 
of (A) acetylcholine (n=6 per group) and (B) adenosine (n=6 per group). Data are presented 
as mean ± SEM. * P< 0.05 vs statistically determined asymptote of the response in LZR 
using Welch’s t-test. 
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Figure 8: Constriction of ex vivo middle cerebral arteries 
The constriction of isolated middle cerebral arteries from lean Zucker rats (LZR) and obese 
Zucker rats (OZR) in response to increasing (A) bath concentrations of 5-
hydroxytryptamine at 80% mean arterial pressure (n=7) and (B) intraluminal pressure 
(n=13). Data are presented as mean ± SEM. *P< 0.05 vs response in LZR using (A) 
repeated measured mixed ANOVA and (B) Welch’s t-test comparing the slope, 𝛽, of the 
linear regression performed between 60-140 mmHg. 
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Figure 9: Myogenic response of ex vivo middle cerebral arteries challenged with 
ACh, adenosine, or 5-HT 
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The response of middle cerebral arteries from lean Zucker rats (LZR) and obese Zucker 
rats (OZR) in response to increasing intraluminal pressure. Data presented as mean ± 
SEM, are presented for vessels under control conditions following challenge with (A) 
acetylcholine (10-6 bath concentration) (n=4 per group), (B) adenosine (10-4 M bath 
concentrations) (n=4 per group), and (C) 5-hydroxytryptamine (10-6 M bath 
concentrations) (n=5 per group). The slope, 𝛽, of the linear regression performed between 
60-140 mmHg and average middle cerebral artery lumen diameter, D, across the same 
pressure range are presented in the inset legend. *P< 0.05 vs LZR diameter (significant 
group effect in repeated measures mixed ANOVA) 𝜙P< 0.05 vs control diameter 
(significant agonist effect in repeated measures mixed ANOVA). 
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Figure 10: Passive mechanical response of ex vivo middle cerebral arteries under 
Ca2+-free conditions. 
The mechanical biophysical properties of the wall of isolated middle cerebral arteries 
from lean Zucker rats (LZR) and obese Zucker rats (OZR) (n=7 per group) under Ca2+ -
free conditions following increasing intraluminal pressure. Mean ± SEM are presented 
for (A) arteriolar lumen diameter, and (B) incremental distensibility of the vessel wall. 
44 
44 
No significant differences were determined between LZR and OZR using repeated 
measures mixed ANOVA. 
3.3 Altered Expression of Endothelial Cell Function 
Genes  
Six of 84 total endothelial cell function related genes examined with the Rat Endothelial 
Cell Biology RT2 Profiler PCR Array demonstrated significant up/down regulation in 
expression (Table 2A). Genes related to thrombosis, oxygen stress, and chronic 
inflammation including Cxcl4, Cxcr5, and Xdh were found to be significantly upregulated 
in OZR, and genes related to COX-2 expression including Ptgs2, Tnf-1, and Anxa5 were 
found to be significantly downregulated. IL-3 was the most up-regulated gene identified in 
OZR in the PCR array but the changes were not significant. Validation qPCR for 6 
significantly differentially expressed genes in PCR array demonstrated similar significant 
changes in expression of Cxcl4, Cxr5, Xdh, and Tnf-1 using 6 rats per group (Table 2B).  
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A 
Gene Symbol Fold Increase P-value 
Cxcl4/Pf4 2.06 0.01 
Cxcr5 1.67 < 0.01 
Xdh 1.59 0.04 
B 
Gene Symbol Fold Decrease P-value 
Ptgs-2 1.82 0.02 
Tnf 1.48 <0.01 
Anxa5 1.12 0.04 
Table 2: Select endothelial cell function related genes either upregulated or 
downregulated in PCR array 
Selected endothelial cell function related genes either upregulated (Table 2A) or 
downregulated (Table 2B) in PCR array; n=4/group Abbreviations: Cxcl4, CXC motif 
ligand 4; Pf4, platlet factor 4; Cxcr5, CXC motif receptor 5; Xdh, xanthine dehydrogenase, 
Ptgs2, prostaglandin-endoperoxide synthase 2; tnf, tumor necrosis factor; Anxa5, Annexin 
V. 
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A 
Gene Symbol Fold Increase P-value 
Cxcl4/Pf4 2.06 < 0.01 
Cxcr5 1.14 0.03 
Xdh 2.07 < 0.01 
B 
Gene Symbol Fold Decrease P-value 
Tnf 1.63 <0.01 
Table 3: Select endothelial cell function related genes either upregulated or 
downregulated in PCR validation 
Select endothelial cell function related genes either up regulated (Table 3A) or 
downregulated (Table 3B) in validation qPCR (Table 2B; n = 6/group). Abbreviations 
Cxcl4, CXC motif ligand 4; Pf4, platlet factor 4; Cxcr5, CXC motif receptor 5; Xdh, 
xanthine dehydrogenase, tnf, tumor necrosis factor. 
3.4 Morris Water Maze 
To test for spatial learning capacity, rats were trained on a MWM protocol with six learning 
trials at 1 h intervals to learn the location of a hidden platform. OZR demonstrated impaired 
spatial learning capacity as measured by an increase average time to reach the platform in 
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trials 2-6 (Figure 11A). In the probe test, performed 24 h later where the platform was 
removed, and the rats’ memory of the platform location during 90 s probe test was inferred 
by preference for the target quadrant in which the platform was previously located during 
the learning trials. The OZR group showed a significant preference for the target quadrant 
compared to LZR (Figure 11B). Swim strategies for proportion of swim time in 
thigmotaxis, annulus, annulus outside target quadrant, and allocentric navigation were 
compared between groups (Figure 11C). Only the proportion of time spent in allocentric 
navigation as estimated by a subjective measure of when the rat was swimming toward the 
platform area was significantly greater in OZR. To determine if there were potentially 
confounding differences in visual perception or swim speed these variables were evaluated 
on 4 cued trials with a visible platform after all MWM testing was complete. No differences 
were observed in swim time to platform or swim speed in these trials. 
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Figure 11: Morris Water Maze 
Data presented as mean ± SEM describing the Morris Water Maze (A) learning represented 
by the average time to locate the platform across learning trials 2-6 for lean Zucker rats 
(LZR) compared to obese Zucker rats (OZR) (n=8 per group). Response during the 90 s 
probe test for (B) the proportion of time spent in the target quadrant (C) and swim strategies 
used. Refer to figure 6 for areas used to quantify swim strategies. *P< 0.05 vs LZR using 
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repeated measures mixed ANOVA for (A) and (B) showing a significant effect for group 
and (C) Welch’s t-test. Abbreviations: OTQ, outside target quadrant; Nav, navigation. 
3.5 Operant Conditioning Chamber Tasks 
In the visual cue discrimination task the number of trials needed to reach the training 
criterion of 8 consecutive correct lever presses was not different suggesting that learning 
was not different in this task (Figure 12A). The next day in a 20-trials retrieval test for 
memory of the visual cue discrimination task demonstrated no impairment in visual cue 
memory in OZR (Figure 12C). Directly following the visual cue retrieval task attentional 
set shifting was evaluated over 120 trials where the rats were to ignore the cue light and 
learn a spatial strategy where only pressing one of the levers (either left or right) would 
produce a food reward. Again, no differences in the number of trials to reach 8 consecutive 
correct lever presses were found (Figure 13A) and in the 20-trial retrieval test no 
impairments in memory were detected (Figure 13C). Directly following set shift retrieval, 
the reversal task was evaluated over 120 trials again with no differences detected in the 
number of trials to reach criterion (Figure 14A). Error types were then categorized as 
perseverative, regressive, or never-reinforced as have been previously described (Levit et 
al., 2017), along with the number of omissions, for visual cue discrimination (Figure 12B), 
set shift (Figure 13B), and reversal (Figure 14B) tasks. Perseverative errors are those that 
follow the previously reinforced visual cue, which tend to occur most often in the early 
trials before the new spatial cue is learned. Regressive errors were defined as errors 
following the previous cue that occur after the rat has learned the newly rewarded spatial 
strategy. Specifically, once <75% of responses follow the previously learned strategy 
subsequent errors are considered regressive. Never-reinforced errors are those that follow 
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neither the previous visual cue nor the newly rewarding spatial strategy. No differences 
were observed in types of errors committed; however, OZR had significantly more 
omissions in the visual cue discrimination task when compared to LZR. 
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Figure 12: Visual discrimination task 
The response of visual cue discrimination task, mean ± SEM, for lean Zucker rats (LZR) 
and obese Zucker rats (OZR) (n=8 per group) for (A) number of trials required to achieve 
8 correct consecutive responses, (B) the types of errors committed during the 120 trials, 
and (C) the percentage of correct responses in 20 trials after a 24 h delay. *P< 0.05 vs 
response of LZR using Welch’s t-test. 
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Figure 13: Set shift task 
The response of set shift task, mean ± SEM, for lean Zucker rats (LZR) and obese Zucker 
rats (OZR) (n=8 per group) for (A) number of trials to achieve 8 correct consecutive 
responses, (B) the types of errors committed during the 120 trials, and (C) the percentage 
of correct responses after a 24 h delay. No significant differences were determined 
between LZR and OZR using Welch’s t-test. 
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Figure 14: Reversal task 
The response of reversal task, mean ± SEM, for lean Zucker rats (LZR) and obese Zucker 
rats (OZR) (n=8 per group) for (A) number of trials required to achieve 8 correct 
consecutive responses, and (B) the types of errors committed during the 120 trials. No 
significant differences were determined between LZR and OZR using Welch’s t-test. 
3.6 Immunohistochemistry 
In order to examine for the presence of increased neuroinflammation the % area coverage 
of OX6-positive microglia and GFAP-positive astrocytes were used as a biomarker of 
activated microglia and reactive astrocytes in LZR versus OZR. Digital image analyses 
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showed that  the % area coverage by OX6-positive microglia was not affected by group in 
all anatomical regions of interests (corpus callosum, supraventricular corpus callosum, 
hippocampus, and internal capsule) (Figure 15A). No group differences in area coverage 
by activated reactive GFAP-positive astrocytes were observed (Figure 15C).  
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Figure 15: Markers of neuroinflammation in white matter regions and the 
hippocampus 
Cross sectional % area coverage, mean ± SEM, by (A) OX6-positive microglial and (C) 
GFAP-positive astrocytes in the CC: corpus callosum, SVCC: supraventricular corpus 
callosum, Cing: cingulum, Hipp: hippocampus, and IC: internal capsule of lean Zucker 
rats (LZR) and obese Zucker rats (OZR) (n=6 per group). No significant effect of group 
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(LZR vs OZR) was observed using a repeated measured mixed ANOVA. (B) 
Representative micrographs of OX6-positive microglia area coverage in the corpus 
callosum, scale bar = 100 𝜇𝑚. 
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4 Discussion 
MetS is a chronic disease that can lead to long-term elevations in cardiovascular and 
cerebrovascular disease which may manifest in the form of stroke, TIA, or inappropriate 
cerebral perfusion (Chen et al., 2017). Precise control of cerebral vascular tone is a crucial 
contributor to these poor outcomes that involves the integration of various signals from the 
endothelium, vascular smooth muscle and others to determine an appropriate level of tone. 
The MCA is a vessel of particular interest because of its significant role in cerebral blood 
flow regulation and because it is a frequent site of occlusion/stroke (Yu et al., 2018). 
Therefore, changes to the reactivity of MCA associated with the development of MetS 
provide insights into how altered aspects of disease development can impact the control of 
blood flow within the brain. In general the vascular reactivity experiments revealed two 
overarching changes to the regulation of cerebral vascular tone to the OZR at this age 
enhanced myogenic tone and endothelial dysfunction.  
4.1 Vascular Reactivity 
This study observed impaired endothelial function in OZR as measured by impaired 
dilation to ACh, which has been consistently demonstrated in OZR (Brooks et al., 2015, 
2018a, 2018b) and is considered a hallmark of MetS. Dilation of the MCA in response to 
ACh is both endothelium and NOS dependent as evidenced by a severely blunted response 
in endothelium denudated vessels or in the presence of the NOS inhibitor L-NAME 
(Sylvester et al., 2002). The impaired dilation is likely due to a combination of decreased 
NO bioavailability with the potential for some contribution of altered arachidonic acid 
metabolism brought on by the presence of ROS and inflammation. The pro-oxidant 
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environment in OZR leads to increased scavenging by ROS decreasing the NO 
bioavailability and limiting its ability to hyperpolarize VSMC thus impairing dilation. This 
decrease in NO bioavailability is supported by measurements from pooled arteries in 
previous studies showing both decreased NO and an increase in the ROS, H2O2 (Brooks et 
al., 2015, 2018b). TEMPOL, a superoxide dismutase mimetic, is frequently used to assess 
the contributions of reactive oxygen species in altering vascular reactivity (Phillips et al., 
2005; Halvorson et al., 2019) which has been shown to improve endothelial function in 
environments of increased oxygen stress. This includes the cerebral circulation and other 
vascular beds, in multiple models of metabolic disease (goto-kakizaki, OZR) while having 
no significant effect on healthy controls (Phillips et al., 2005). Although outside the scope 
of this thesis, pervious work on the OZR has demonstrated increased plasma cytokines, 
chemokines, and other biomarkers associated with ROS and inflammation including N-
tyrosine, TNF-a, and MCP-1 (Brooks et al., 2015). The gene expression data in this thesis 
support the evidence in the literature citing increased markers of inflammation and oxygen 
stress as here xanthine oxidase expression, and although not statistically significant 
interleukin-3 (Il-3) expression were increased. Xanthine oxidase has been implicated in 
endothelial injury and hypoxia as a major generator of ROS in numerous studies by acting 
as a catalyst in the formation of uric acid from xanthine releasing ROS (Berry & Hare, 
2004; Cai, 2005). Its overexpression can induce a cycle of ROS leading to impaired dilation 
and thus hypoxia which has been well demonstrated to further induce xanthine oxidase 
activation (Kayyali et al., 2001; Sohn et al., 2003). Although the observed increased 
expression of IL-3 in this study was not significant largely due to extremely low expression 
in LZR, since an approximately 9.5-fold increase was observed it should be noted that IL-
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3 has been proposed as a marker of chronic inflammation (Dougan et al., 2019) and thus 
likely contributes to the pro-inflammatory environment in OZR.  
 
A shift in AA metabolism towards constrictor metabolites and away from dilators, would 
also contribute to impaired dilation and has been previously measured using pooled 
arteries. Previous work has found a decrease in NO bioavailability and PGI2 along with 
increased TxA2 and H2O2 (Halvorson et al., 2019). COX-2 is a major contributor to the 
generation of PGI2 in the endothelium of the MCA (Flavahan, 2007; Funk & FitzGerald, 
2007). Therefore, the reduced expression of COX-2 in OZR in this thesis further supports 
that there are alterations in arachidonic acid metabolism in OZR. However, it is difficult to 
draw conclusions from the PCR data alone since COX-2 catalyzes the synthesis of 
prostaglandin H2 which may then be used to form either the dilator PGI2 or constrictor 
TxA2 catalyzed by prostacyclin synthase or thromboxane synthase respectively. Although 
it’s difficult to discern the implications of down regulation of COX-2, its importance in 
health is supported by disastrous results in its absence including the death of 30-40% of 
knockout mice pups within 48 h of birth from patent ductus arteriosus (Loftin et al., 2001), 
with surviving mice having significantly shorter life spans than wild-type (Morham et al., 
1995). Murine models of cardiovascular disease have also established the negative 
consequences of COX-2 inhibitors on decreasing protection from thrombogenesis, 
hypertension, and atherogenesis in vivo (Tilo et al., 2006). These inhibitors were disastrous 
in their clinical outcomes enhancing the probability of coronary atherothrombosis, heart 
failure, and increasing long-term cardiovascular risk (Patrono, 2016). 
 
60 
60 
The reactivity to adenosine was also investigated due to its involvement with metabolic 
control and to provide a secondary stimulus for dilation with a different mechanistic action 
than ACh. In contrast to ACh, OZR did not demonstrate significant changes to adenosine 
sensitivity suggesting there is a different sensitivity to MetS for different mechanisms of 
vasodilation. Compared to ACh the involvement of NO in adenosine-mediated dilation is 
much less pronounced (Prentice & Hourani, 2000; Murrant et al., 2014). Impairment in 
dilation to adenosine is more indicative of K+ channels along with structural changes than 
NO bioavailability because of the direct hyperpolarizing effects of adenosine on the 
vasculature (Paisansathan et al., 2010). No difference in adenosine reactivity has been 
shown in both gracilis and cremaster muscle arterioles of diabetic rats (Frisbee et al., 2019), 
as well as in gracilis arterioles and middle cerebral arteries of OZR at this age but 
impairments could develop if tested at a later timepoint with more pronounced vascular 
remodeling (Butcher et al., 2013). Although there is strong evidence for the presence of 
endothelial dysfunction leading to impaired dilator reactivity, the impaired dilator 
reactivity could also be a result of an increase in vascular tone from myogenic activation, 
or constrictor reactivity. 
 
In this study both an increase in resting tone and constrictor reactivity in response to 5-HT 
was observed in OZR as had been previously demonstrated (Phillips et al., 2005). The 
previously discussed endothelial dysfunction likely contributes to the hyperreactivity to 
constrictor stimuli by decreasing the buffering effect of endothelium-derived 
hyperpolarizing factors. However, since vascular hyper-reactivity associated with 
hyperglycemia and hypertension has been shown to be mediated by increased activation of 
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voltage-gated Ca2+ channels and protein kinase C in arteriolar smooth muscle, even in 
endothelium-denuded vessels, there are also likely other mechanisms at play (Ungvari et 
al., 1999; Wendler et al., 2001). Patients with T2DM had significantly higher 5-HT 
induced constriction on both the arterial and venous sides (internal thoracic artery and 
saphenous vein) (Matsuo et al., 2011; Yokota et al., 2016) due to higher level of 5-HT2A 
receptors. Similar results were found by Liu and colleagues (Liu & Folz, 2004) who found 
enhanced 5-HT-induced constriction in intrapulmonary arteries of similar diameter to 
MCA after removal of the endothelium or treatment with L-NAME. Interestingly they also 
showed increased constrictor response with xanthine and xanthine oxidase treatment, an 
enzyme the current study found to be overexpressed in OZR (Liu & Folz, 2004). Increased 
expression of xanthine oxidase may be contributing to the observed enhanced 
vasoconstriction by increasing superoxide levels which has been shown to modulate 
vasoconstriction through various mechanisms both by acting directly on the vascular 
smooth muscle or by disrupting endothelium-derived relaxing or contracting factor 
(Kasemsri & Armstead, 1997; Liu & Folz, 2004). 
 
This study also demonstrated an increase in myogenic activation and agrees with several 
others demonstrating increased myogenic activation with MetS in OZR (Phillips et al., 
2005). The increase in myogenic activation may be due to a loss of endothelium-dependent 
buffering of constrictor responses. Blunted production of metabolites involved in dilation 
such as NO or PGI2, would result in increased constriction in response to higher 
intralumenal pressure; therefore, endothelial dysfunction may also be contributing to an 
increase in myogenic activation. This is supported by a decrease in myogenic activation in 
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the MCA of OZR with acute treatment of TEMPOL (Phillips et al., 2005). Although this 
reduced the discrepancy between OZR and LZR, increased myogenic activation was still 
observed compared to the lean counterpart and that increased myogenic tone is elevated in 
endothelium-denuded vessels suggests there are other factors at play.  The greatest risk 
factor associated with increased myogenic activation is hypertension (Baumbach & 
Heistad, 1989; Baumbach & Hajdu, 1993). Increased tone is observed in animal models of 
hypertension and is usually absent in models lacking hypertensive stimuli (Halvorson et 
al., 2019). It is thought that increased myogenic activation may be a protective mechanism 
for hypertension in order to limit the potential for edema caused by high pressures in the 
microcirculation and may represent a chronic contributor to blood flow autoregulation. 
This study demonstrated mild non-significant remodeling of the MCA as measured by 
lumen diameter and incremental wall distensibility across a range of pressures under Ca2+-
free conditions. Greater remodeling can be expected as these animals age leading to more 
pronounced effects, as seen by Harris and colleagues (Harris et al., 2005) in diabetic and 
hypertensive rats, characterized by increased wall-to-lumen ratio from medial hypertrophy 
and collagen deposition. However, at this age, it is possible that the change in wall 
mechanics was limited because of the presence of new collagen deposition rather than 
mature collagen, which has less impact on the distensibility of vessels. Interestingly, 
hyperglycemia has also been implicated in changes to myogenic tone with both decreased 
and increased myogenic tone being observed. In the mesenteric arteries of GK rats, the 
reduced myogenic activation was improved by glycemic control with metformin 
(Sachidanandam et al., 2009a); however, they also suggested that hyperglycemia can 
activate endothelin receptors enhancing myogenic tone (Sachidanandam et al., 2009b). 
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Taken together these data on the vascular reactivity of the MCA in OZR suggest 
endothelial dysfunction with increased activation of the VSMC.  
 
Most studies of cerebrovascular reactivity investigate the response to a single stimulus 
because the simpler interpretations of mechanistic changes; however, in a physiological 
setting, the cerebral vasculature is constantly responding to a multitude of inputs which 
must be processed in order to determine a certain level of tone. In addition to testing the 
response to individual stimuli this study integrated either dilator (ACh, adenosine) stimuli 
or the constrictor 5-HT with the myogenic response. Integration of multiple stimuli may 
provide more physiologically relevant insights into the impairments occurring in MetS and 
is therefore, of interest. These results follow similar trends to the individual responses 
discussed and demonstrates that in a physiological setting the individual impairments in 
blunted dilation and hyper-constriction leads to a decreased ability to promote flow.  
 
4.2 Cognitive Testing 
This limited ability of the MCA to promote flow in OZR may lead to instances of 
hypoperfusion in cerebral tissue which has the potential to result in cognitive impairment. 
The documented interaction of cerebrovascular disease and cognitive impairment in Mets 
as well as the presence of both depressive and anxious symptoms in the OZR (Brooks et 
al., 2018b) encouraged an investigation into the cognitive outcomes associated with the 
OZR. The MWM demonstrated impaired spatial learning in OZR as measured by increased 
average latency to reach the platform in learning trials two to six. Impaired spatial memory 
has previously been demonstrated in a similar model of MetS, also based on hyperphagia, 
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named the Otsuka Long-Evans Tokushima fatty (OLETE) rats. They have impaired spatial 
memory in both the MWM (Li et al., 2002) and radial arm maze (Nomoto et al., 1999) 
which were partially attributed to impaired vasoreactivity to insulin without changes to 
bulk blood flow. Also of note is an increased proportion of time spent in the target quadrant 
during the probe trial, suggesting the potential for either decreased behaviour flexibility or 
better memory. However, since improved memory was not demonstrated in set shifting 
tasks this is unlikely. The interpretation of enhanced memory in OZR would also go against 
some previous work in 4 month old OZR performing a go/no-go delayed alternation task 
where they performed worse when long intervals between trials were used, suggesting a 
memory impairment (Winocur et al., 2005) which they attributed to reduced plasma 
membrane association of glucose transporter type 4 (GLUT4) although no learning 
impairment was found.  
The cognitive impairments to OZR and other similar models appear to be task dependent. 
No changes were observed in the Barnes maze with OLETE rats at 40 weeks of age or in 
Sprague-Dawley rats on an ultra-processed diet termed the cafeteria diet at 4 months of 
age, or in learning go/no-go task in OZR (Gomez-Smith et al., 2016; Olver et al., 2017) 
just as the present study found no difference in set shift task learning, memory, or 
behavioural flexibility. Interestingly in the operant conditioning tasks OZR had 
significantly more omissions in the visual cue discrimination task and trended towards 
increased omissions over the lean controls in the other two tasks. Generally, omissions are 
associated with task motivation and so it is interesting that the OZR, a model of MetS based 
on hyperphagia, would demonstrate lower motivation for a task that involves a food 
reward. Loss of motivation has been shown in rats on a refined foods diet associated with 
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obesity and diabetes in an operant conditioning chamber task (Blaisdell et al., 2017). Since 
this refined foods diet model has been associated with depression and previous work in the 
OZR has demonstrated the presence of depressive symptoms through increased coat score, 
latency to begin consumption in novelty supressed feeding, and latency to begin grooming 
after a sucrose spray (Brooks et al., 2018b), the increased omissions in the operant 
conditioning chamber tasks could be a reflection of depressive symptoms and warrants 
further investigation. 
 
4.3 Neuroinflammation 
These mild cognitive impairments do not appear to be related to inflammation in the white 
matter or hippocampus at this age since neither showed increased OX6 positive microglia 
or GFAP positive astrocytes in OZR. These results go against the clinical findings that 
lesions in the white matter,  which has been shown to be highly susceptible to pathological 
changes particularly vascular disruption (Li et al., 2016; Wang et al., 2016), tend to be 
present well before symptoms of cognitive impairment start to appear (Brickman et al., 
2015; Lee et al., 2016). In a study investigating the comorbidity of MetS and dementia, the 
TgAPP21 rat model of Alzheimer’s disease was fed a hypercaloric diet high in fat and 
simple sugars. The transgenic rats displayed both increased microglial activation and 
astrogliosis located primarily in the white matter; however, the hypercaloric diet alone was 
not sufficient to result in any inflammatory changes between wild type rats. 
The high fat diet used to induce MetS was associated with an inability to improve path 
efficiency in a 16 trials MWM protocol performed over 4 days, although all other behaviour 
measures were unchanged (Ivanova et al., 2020). Also of note is that the rats in that study 
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were significantly older (9 months compared to 18 weeks) then the rats used in this thesis. 
This likely contributes to the absence of any significant neuroinflammation found in these 
rats since 18 weeks is significantly younger than the equivalent of mid-life in humans 
where these risk factors being to appear (Andreollo et al., 2012). This may explain why 
this thesis did not find the mild cognitive impairments to be associated with any significant 
neuroinflammation.  
4.4 General Discussion and Conclusions 
This study describes some of the impairment to cerebrovascular tone regulation that 
develop in the OZR model of MetS related to both vascular reactivity and endothelial cell 
function related gene expression. Endothelial dysfunction was present in the MCA of OZR 
demonstrated by blunted dilation in response to ACh, while an enhanced constrictor 
response to 5-HT and pressure was also demonstrated. These changes to cerebrovascular 
tone regulation are the results of the genesis of a proinflammatory and prooxidant 
environment in the OZR. Given the demonstrated altered cerebrovascular reactivity with 
evidence of mild cognitive dysfunction, this study provides a framework for additional 
investigation into mechanistic pathways and potential therapeutics for restoring function 
in the cerebral circulation and improving current negative outcomes associated with MetS 
including vascular cognitive impairment. 
 
67 
67 
References 
Ainslie PN, Ashmead JC, Ide K, Morgan BJ & Poulin MJ (2005). Differential responses 
to CO2 and sympathetic stimulation in the cerebral and femoral circulations in 
humans. J Physiol 566, 613–624. 
Alfaro FJ, Lioutas V-A, Pimentel DA, Chung C-C, Bedoya F, Yoo W-K & Novak V 
(2016). Cognitive decline in metabolic syndrome is linked to microstructural white 
matter abnormalities. J Neurol 263, 2505–2514. 
Anand-Srivastava MB, Franks DJ, Cantin M & Genest J (1982). Presence of “Ra” and 
“P”-site receptors for adenosine coupled to adenylate cyclase in cultured vascular 
smooth muscle cells. Biochem Biophys Res Commun 108, 213–219. 
Andreollo NA, Santos EF dos, Araújo MR & Lopes LR (2012). Rat’s age versus human’s 
age: what is the relationship? Arq Bras Cir Dig 25, 49–51. 
Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG & Tzeng E (2005). Nitric oxide 
modulates vascular inflammation and intimal hyperplasia in insulin resistance and 
the metabolic syndrome. Am J Physiol Hear Circ Physiol 289, H228–H236. 
Bari F, Louis TM & Busija DW (1998). Effects of Ischemia on Cerebral Arteriolar 
Dilation to Arterial Hypoxia in Piglets. Stroke 29, 222–228. 
Baumbach GL, Faraci FM & Heistad DD (1994). Effects of local reduction in pressure on 
endothelium-dependent responses of cerebral arterioles. Stroke 25, 1456–1462. 
Baumbach GL & Hajdu MA (1993). Mechanics and composition of cerebral arterioles in 
renal and spontaneously hypertensive rats. Hypertens (Dallas, Tex  1979) 21, 816–
826. 
Baumbach GL & Heistad DD (1989). Remodeling of Cerebral Arterioles in Chronic 
Hypertension. Hypertension 13, 968–972. 
Bayliss WM (1902). On the local reactions of the arterial wall to changes of internal 
pressure. J Physiol 28, 220–231. 
Berne RM, Richard Winn H & Rubio R (1981). The local regulation of cerebral blood 
flow. Prog Cardiovasc Dis 24, 243–260. 
Von Bernhardi R & Eugenín J (2004). Microglial reactivity to β-amyloid is modulated by 
astrocytes and proinflammatory factors. Brain Res 1025, 186–193. 
Berry CE & Hare JM (2004). Xanthine oxidoreductase and cardiovascular disease: 
Molecular mechanisms and pathophysiological implications. J Physiol 555, 589–
606. 
Binks AP, Cunningham VJ, Adams L & Banzett RB (2008). Gray matter blood flow 
change is unevenly distributed during moderate isocapnic hypoxia in humans. J Appl 
Physiol 104, 212–217. 
Blaisdell AP, Biedermann T, Sosa E, Abuchaei A, Youssef N & Bradesi S (2017). An 
obesogenic refined low-fat diet disrupts attentional and behavioral control processes 
in a vigilance task in rats. Behav Processes 138, 142–151. 
68 
68 
Boutayeb A, Boutayeb S & Boutayeb W (2013). Multi-morbidity of non communicable 
diseases and equity in WHO Eastern Mediterranean countries. Int J Equity Health 
12, 60. 
Bray GA (1977). The Zucker fatty rat: a review. Fed Proc 36, 148–153. 
Brickman AM, Zahodne LB, Guzman VA, Narkhede A, Meier IB, Griffith EY, 
Provenzano FA, Schupf N, Manly JJ, Stern Y, Luchsinger JA & Mayeux R (2015). 
Reconsidering harbingers of dementia: Progression of parietal lobe white matter 
hyperintensities predicts Alzheimer’s disease incidence. Neurobiol Aging 36, 27–32. 
Brooks S, Brnayan KW, DeVallance E, Skinner R, Lemaster K, Sheets JW, Pitzer CR, 
Asano S, Bryner RW, Olfert IM, Frisbee JC & Chantler PD (2018a). Psychological 
stress-induced cerebrovascular dysfunction: the role of metabolic syndrome and 
exercise. Exp Physiol 103, 761–776. 
Brooks SD, DeVallance E, D’Audiffret AC, Frisbee SJ, Tabone LE, Shrader CD, Frisbee 
JC & Chantler PD (2015). Metabolic syndrome impairs reactivity and wall 
mechanics of cerebral resistance arteries in obese Zucker rats. Am J Physiol - Hear 
Circ Physiol 309, H1846–H1859. 
Brooks SD, Hileman SM, Chantler PD, Milde SA, Lemaster KA, Frisbee SJ, Shoemaker 
JK, Jackson DN & Frisbee JC (2018b). Protection from chronic stress-and 
depressive symptom-induced vascular endothelial dysfunction in female rats is 
abolished by preexisting metabolic disease. Am J Physiol Hear Circ Physiol 314, 
1085–1097. 
Brown AM & Ransom BR (2007). Astrocyte glycogen and brain energy metabolism. 
Glia 55, 1263–1271. Available at: www.interscience.wiley. [Accessed August 14, 
2018]. 
Burnstock G (1985). Neurogenic Control of Cerebral Circulation. Cephalalgia 2, 25–33. 
Busse R, Förstermann U, Matsuda H & Pohp U (1984). The role of prostaglandins in the 
endothelium-mediated vasodilatory response to hypoxia*. Pflugers Arch 401, 77–
83. 
Busse R, Pohl U, Kellner C & Klemm U (1983). Endothelial Cells are Involved in the 
Vasodilatory Response to Hypoxia*. Pflugers Arch 397, 78–80. 
Butcher JT, Goodwill AG & Frisbee JC (2012). The ex vivo Isolated Skeletal 
Microvessel Preparation for Investigation of Vascular Reactivity. J Vis Exp 62, 
e3674. 
Butcher JT, Goodwill AG, Stanley SC & Frisbee JC (2013). Differential impact of dilator 
stimuli on increased myogenic activation of cerebral and skeletal muscle resistance 
arterioles in obese zucker rats. Microcirculation 20, 579–589. 
Cai H (2005). Hydrogen peroxide regulation of endothelial function: Origins, 
mechanisms, and consequences. Cardiovasc Res 68, 26–36. 
Carter RW & Kanagy NL (2002). Tyrosine kinases regulate intracellular calcium during 
2-adrenergic contraction in rat aorta. Am J Physiol Hear Circ Physiol 283, H1673–
H1680. 
69 
69 
De Carvalho Vidigal F, Bressan J, Babio N & Salas-Salvadó J (2013). Prevalence of 
metabolic syndrome in Brazilian adults: A systematic review. BMC Public Health 
13, 1198. 
Chantler PD & Frisbee JC (2015). Arterial Function in Cardio-Metabolic Diseases: From 
the Microcirculation to the Large Conduits. Prog Cardiovasc Dis 57, 489–496. 
Chantler PD & Larkin KT (2020). Cardiovascular Implications of Stress and Depression. 
Chen W et al. (2017). Recurrent stroke in minor ischemic stroke or transient ischemic 
attack with metabolic syndrome and/or diabetes mellitus. J Am Heart Assoc 6, 1–12. 
Cipolla MJ (2010). The Cerebral Circulation. Morgan & Claypool Life Sciences. 
Cipolla MJ, Liebeskind DS & Chan SL (2018). The importance of comorbidities in 
ischemic stroke: Impact of hypertension on the cerebral circulation. J Cereb Blood 
Flow Metab 38, 2129–2149. 
Dandona P, Aljada A, Chaudhuri A, Mohanty P & Garg R (2005). Metabolic Syndrome 
A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, 
and Inflammation. Circulation 111, 1448–1454. 
Davies PF (2009). Hemodynamic shear stress and the endothelium in cardiovascular 
pathophysiology. Nat Clin Pract Cardiovasc Med 6, 16–26. 
Davis MJ & Hill MA (1999). Signaling Mechanisms Underlying the Vascular Myogenic 
Response. Physiol Rev 79, 387–423. 
Davis MJ & Sikes PJ (1990). Myogenic responses of isolated arterioles: test for a rate-
sensitive mechanism Myogenic re-sponses of isolated arterioles: test for a rate-
sensitive mechanism. Am J Physiol Hear Circ Physiol 28, H1890–H1900. 
DeVallance E, Fournier SB, Donley DA, Bonner DE, Lee K, Frisbee JC & Chantler PD 
(2015). Is obesity predictive of cardiovascular dysfunction independent of 
cardiovascular risk factors? Int J Obes 39, 244–253. 
Diamond A (2013). Executive functions. Annu Rev Psychol 64, 135–168. 
Donley DA, Fournier SB, Reger BL, DeVallance E, Bonner DE, Olfert IM, Frisbee JC & 
Chantler PD (2014). Aerobic exercise training reduces arterial stiffness in metabolic 
syndrome. J Appl Physiol 116, 1396–1404. 
Dougan M, Dranoff G & Dougan SK (2019). GM-CSF, IL-3, and IL-5 Family of 
Cytokines: Regulators of Inflammation. Immunity 50, 796–811. 
El-Yazbi AF & Abd-Elrahman KS (2017). ROK and arteriolar myogenic tone generation: 
Molecular evidence in health and disease. Front Pharmacol 8, 1–10. 
Ferdinand KC, Rodriguez F, Nasser SA, Caballero AE, Puckrein GA, Zangeneh F, 
Mansour M, Foody JM, Pemu PE & Ofili EO (2014). Cardiorenal metabolic 
syndrome and cardiometabolic risks in minority populations. CardioRenal Med 4, 
1–11. 
Filley CM (2005). White matter and behavioral neurology. Ann N Y Acad Sci 1064, 162–
183. 
70 
70 
Flavahan NA (2007). Balancing prostanoid activity in the human vascular system. Trends 
Pharmacol Sci 28, 106–110. 
Frisbee JC (2005). Hypertension-independent microvascular rarefaction in the obese 
Zucker rat model of the metabolic syndrome. Microcirculation 12, 383–392. 
Frisbee JC, Lewis MT, Kasper JD, Chantler PD & Wiseman RW (2019). Type 2 diabetes 
mellitus in the Goto-Kakizaki rat impairs microvascular function and contributes to 
premature skeletal muscle fatigue. J Appl Physiol 126, 626–637. 
Frisbee JC, Maier KG, Falck JR, Roman RJ & Lombard JH (2002a). Integration of 
hypoxic dilation signaling pathways for skeletal muscle resistance arteries. Am J 
Physiol Regul Integr Comp Physiol 283, R309–R319. 
Frisbee JC, Maier KG & Stepp DW (2002b). Oxidant stress-induced increase in 
myogenic activation of skeletal muscle resistance arteries in obese Zucker rats. Am J 
Physiol - Hear Circ Physiol 283, H2160–H2168. 
Fu J & Prasad HC (2014). Changing epidemiology of metabolic syndrome and type 2 
diabetes in Chinese youth. Curr Diab Rep 14, 447. 
Fujii K, Heistad DD & Faraci FM (1991). Flow-Mediated Dilatation of the Basilar Artery 
In Vivo. Circ Res 69, 697–705. 
Funk CD & FitzGerald GA (2007). COX-2 inhibitors and cardiovascular risk. J 
Cardiovasc Pharmacol 50, 470–479. 
Garcia-Roldan J-L & Bevan JA (1991). Augmentation of Endothelium-Independent Flow 
Constriction in Pial Arteries at High Intravascular Pressures. Hypertension 17, 870–
874. 
Garcia-Roldan JL & Bevan JA (1990). Flow-induced constriction and dilation of cerebral 
resistance arteries. Circ Res 66, 1445–1448. 
Gebremedhin D, Gopalakrishnan S & Harder DR (2014). Endogenous events modulating 
myogenic regulation of cerebrovascular function. Curr Vasc Pharmacol 12, 810–
817. 
Gomez-Smith M, Karthikeyan S, Jeffers MS, Janik R, Thomason LA, Stefanovic B & 
Corbett D (2016). A physiological characterization of the Cafeteria diet model of 
metabolic syndrome in the rat. Physiol Behav 167, 382–391. 
González JM, Beatriz S, Conde MV, Fernández-Alfonso MS, González MC & Arribas 
SM (2008). Hypertension increases middle cerebral artery resting tone in 
spontaneously hypertensive rats: role of tonic vasoactive factor availability. Clin Sci 
114, 651–659. 
Gordon GRJ, Choi HB, Ellis-Davies GCR & Macvicar BA (2008). Brain metabolic state 
dictates the polarity of astrocyte control over the cerebrovasculature. Nature 456, 
745–749. 
Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers 
WJ, DeCarli C, Merino JG, Kalaria RN, Vinters H V., Holtzman DM, Rosenberg 
GA, Dichgans M, Marler JR & Leblanc GG (2006). National Institute of 
71 
71 
Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive 
impairment harmonization standards. Stroke 37, 2220–2241. 
Halvorson BD, Whitehead SN, Mcguire JJ, Wiseman RW & Frisbee JC (2019). 
Endothelium-dependent impairments to cerebral vascular reactivity with type 2 
diabetes mellitus in the Goto-Kakizaki rat. J Physiol Regul Integr Comp Physiol 
317, R149–R159. 
Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, 
Fagan SC & Ergul A (2005). Type 2 Diabetes Causes Remodeling of 
Cerebrovasculature via Differential Regulation of Matrix Metalloproteinases and 
Collagen Synthesis Role of Endothelin-1. Diabetes 54, 2638–2644. 
Harry GJ & Kraft AD (2008). Neuroinflammation and microglia: Considerations and 
approaches for neurotoxicity assessment. Expert Opin Drug Metab Toxicol 4, 1265–
1277. 
Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I, Tatematsu S, 
Kumagai H & Saruta T (2002). Altered renal microvascular response in Zucker 
obese rats. Metabolism 51, 1553–1561. 
Heistad DD & Baumbach GL (1992). Cerebral vascular changes during chronic 
hypertension: good guys and bad guys. J Hypertens Suppl 10, S71-5. 
Humphrey JD (2008). Mechanisms of arterial remodeling in hypertension coupled roles 
of wall shear and intramural stress. Hypertension 52, 195–200. 
Iadecola C & Davisson RL (2008). Hypertension and Cerebrovascular Dysfunction. Cell 
Metab 7, 476–484. 
Iadecola C & Gottesman RF (2019). Neurovascular and Cognitive Dysfunction in 
Hypertension: Epidemiology, Pathobiology, and Treatment. Circ Res 124, 1025–
1044. 
Ivanova N, Liu Q, Agca C, Agca Y, Noble EG, Whitehead SN & Cechetto DF (2020). 
White matter inflammation and cognitive function in a co-morbid metabolic 
syndrome and prodromal Alzheimer’s disease rat model. J Neuroinflammation 17, 
1–18. 
Jaggar JH, Porter VA, Lederer WJ & Nelson MT (2000). Calcium sparks in smooth 
muscle. Am J Physiol - Cell Physiol 278, C235-256. 
Jarajapu YPR, Guberski DL, Grant MB & Knot HJ (2008). Myogenic tone and reactivity 
of cerebral arteries in Type II diabetic BBZDR/Wor rat. Eur J Pharmacol 579, 298–
307. 
Johnson FK, Johnson RA, Durante W, Jackson KE, Stevenson BK, Peyton KJ & Johnson 
FK (2006). Metabolic syndrome increases endogenous carbon monoxide production 
to promote hypertension and endothelial dysfunction in obese Zucker rats. Am J 
Physiol Regul Integr Comp Physiol 290, 601–608. 
Jones CJ, Kuo L, Davis MJ & Chilian WM (1993). Myogenic and flow-dependent 
control mechanisms in the coronary microcirculation. Basic Res Cardiol 88, 2–10. 
72 
72 
de Jong J., de Jonge R, Keijzer E & Bradamante S (2000). The role of adenosine in 
preconditioning. Pharmacol Ther 87, 141–149. 
Kasemsri T & Armstead WM (1997). Endothelin production links superoxide generation 
to altered opioid- induced pial artery vasodilation after brain injury in pigs. Stroke 
28, 190–197. 
Kayyali US, Donaldson C, Huang H, Abdelnour R & Hassoun PM (2001). 
Phosphorylation of Xanthine Dehydrogenase/Oxidase in Hypoxia. J Biol Chem 276, 
14359–14365. 
Kazuyama E, Saito M, Kinoshita Y, Satoh I, Dimitriadis F & Satoh K (2009). Endothelial 
dysfunction in the early- and late-stage type-2 diabetic Goto-Kakizaki rat aorta. Mol 
Cell Biochem 332, 95–102. 
Koller A & Toth P (2012). Contribution of flow-dependent vasomotor mechanisms to the 
autoregulation of cerebral blood flow. J Vasc Res 49, 375–389. Available at: 
www.karger.com [Accessed June 4, 2019]. 
Kozora E & Filley CM (2011). Cognitive dysfunction and white matter abnormalities in 
systemic lupus erythematosus. J Int Neuropsychol Soc 17, 385–392. 
Kurtz TW, Morris RC & Pershadsingh HA (1989). The zucker fatty rat as a genetic 
model of obesity and hypertension. Hypertension 13, 896–901. 
Kusano Y, Echeverry G, Miekisiak G, Kulik TB, Aronhime SN, Chen JF & Winn HR 
(2010). Role of adenosine A2 receptors in regulation of cerebral blood flow during 
induced hypotension. J Cereb Blood Flow Metab 30, 808–815. 
Lee S et al. (2016). White matter hyperintensities are a core feature of Alzheimer’s 
disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol 
79, 929–939. 
Levit A, Regis AM, Garabon JR, Oh SH, Desai SJ, Rajakumar N, Hachinski V, Agca Y, 
Agca C, Whitehead SN & Allman BL (2017). Behavioural inflexibility in a 
comorbid rat model of striatal ischemic injury and mutant hAPP overexpression. 
Behav Brain Res; DOI: 10.1016/j.bbr.2017.07.006. 
Levit A, Regis AM, Gibson A, Hough OH, Maheshwari S, Agca Y, Agca C, Hachinski 
V, Allman BL & Whitehead SN (2019). Impaired behavioural flexibility related to 
white matter microgliosis in the TgAPP21 rat model of Alzheimer disease. Brain 
Behav Immun; DOI: 10.1016/j.bbi.2019.02.013. 
Li H & Förstermann U (2013). Uncoupling of endothelial NO synthase in atherosclerosis 
and vascular disease. Curr Opin Pharmacol 13, 161–167. 
Li Q & Puro DG (2001). Adenosine activates ATP-sensitive K+ currents in pericytes of 
rat retinal microvessels: role of A1 and A2a receptors. Brain Res 907, 93–99. 
Li X, Ma C, Sun X, Zhang J, Chen Y, Chen K & Zhang Z (2016). Disrupted white matter 
structure underlies cognitive deficit in hypertensive patients. Eur Radiol 26, 2899–
2907. 
Li XL, Aou S, Hori T & Oomura Y (2002). Spatial memory deficit and emotional 
73 
73 
abnormality in OLETF rats. Physiol Behav 75, 15–23. 
Van Lieshout JJ, Wieling W, Karemaker JM & Secher NH (2003). Syncope, cerebral 
perfusion, and oxygenation. J Appl Physiol 94, 833–848. 
Liu JQ & Folz RJ (2004). Extracellular superoxide enhances 5-HT-induced murine 
pulmonary artery vasoconstriction. Am J Physiol - Lung Cell Mol Physiol; DOI: 
10.1152/ajplung.00006.2004. 
Liu Q & Flavahan NA (1997). Hypoxic dilatation of porcine small coronary arteries : role 
of endothelium and K ATP -channels. Br J Pharmacol 120, 728–734. 
Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer 
MD, Nguyen MT, Hawkins BM, Goulet JL, Smithies O, Koller BH & Langenbach 
R (2001). Failure of ductus arteriosus closure and remodeling in neonatal mice 
dificient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci U S A 98, 
1059–1064. 
Lombard JH, Liu YP, Fredricks KT, Bizub DM, Roman RJ & Rusch NJ (1999). 
Electrical and mechanical responses of rat middle cerebral arteries to reduced Po-2 
and prostacyclin. Am J Physiol Hear Circ Physiol 276, H509–H516. 
López-Farré A, Rodriguez-Feo JA, García-Colis E, Gomez J, López-Blaya A, Fortes J, 
De Andrés R, Rico L & Casado S (2002). Reduction of the soluble cyclic GMP 
vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive 
rats: Effect of the α 1 -receptor blocker doxazosin. J Hypertens 20, 463–470. 
Lue LF, Kuo YM, Beach T & Walker DG (2010). Microglia activation and anti-
inflammatory regulation in alzheimer’s disease. Mol Neurobiol 41, 115–128. 
Lynch FM, Austin C, Heagerty AM & Izzard AS (2006). Adenosine and hypoxic dilation 
of rat coronary small arteries: roles of the ATP-sensitive potassium channel, 
endothelium and nitric oxide. Am J Physiol Hear Circ Physiol 290, H1145–H1150. 
Mandell DM, Han JS, Poublanc J, Crawley AP, Kassner A, Fisher JA & Mikulis DJ 
(2008). Selective Reduction of Blood Flow to White Matter During Hypercapnia 
Corresponds With Leukoaraiosis. Stroke 39, 1993–1998. 
Manso Y, Holland PR, Kitamura A, Szymkowiak S, Duncombe J, Hennessy E, Searcy 
JL, Marangoni M, Randall AD, Brown JT, McColl BW & Horsburgh K (2018). 
Minocycline reduces microgliosis and improves subcortical white matter function in 
a model of cerebral vascular disease. Glia 66, 34–46. 
Matsuo Y, Kuwabara M, Tanaka-Totoribe N, Kanai T, Nakamura E, Gamoh S, Suzuki A, 
Asada Y, Hisa H & Yamamoto R (2011). The defective protein level of myosin light 
chain phosphatase (MLCP) in the isolated saphenous vein, as a vascular conduit in 
coronary artery bypass grafting (CABG), harvested from patients with diabetes 
mellitus (DM). Biochem Biophys Res Commun 412, 323–327. 
Messina EJ, Sun D, Koller A, Wolin MS & Kaley G (1992). Role of Endothelium-
Derived Prostaglandins in Hypoxia-Elicited Arteriolar Dilation in Rat Skeletal 
Muscle. Circ Res 71, 790–796. 
Michinaga S & Koyama Y (2015). Pathogenesis of brain edema and investigation into 
74 
74 
anti-edema drugs. Int J Mol Sci 16, 9949–9975. 
Misiak B, Leszek J & Kiejna A (2012). Metabolic syndrome, mild cognitive impairment 
and Alzheimer’s disease-The emerging role of systemic low-grade inflammation and 
adiposity. Brain Res Bull 89, 144–149. 
Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler 
JF, Kluckman KD, Ledford A, Lee CA & Smithies O (1995). Prostaglandin synthase 
2 gene disruption causes severe renal pathology in the mouse. Cell 83, 473–482. 
Morii S, Ngai AC, Ko KR & Winn HR (1987). Role of adenosine in regulation of 
cerebral blood flow: Effects of theophylline during normoxia and hypoxia. Am J 
Physiol - Hear Circ Physiol 253, H165–H175. 
Murrant CL, Dodd JD, Foster AJ, Inch KA, Muckle FR, Ruiz DA, Simpson JA & Scholl 
JHP (2014). Prostaglandins induce vasodilatation of the microvasculature during 
muscle contraction and induce vasodilatation independent of adenosine. J Physiol 
592, 1267–1281. 
Ng TP, Feng L, Nyunt MSZ, Feng L, Gao Q, Lim ML, Collinson SL, Chong MS, Lim 
WS, Lee TS, Yap P & Yap KB (2016). Metabolic syndrome and the risk of mild 
cognitive impairment and progression to dementia follow-up of the Singapore 
longitudinal ageing study cohort. JAMA Neurol 73, 456–463. 
Ngai AC & Winn HR (1993). Effects of Adenosine and Its Analogues on Isolated 
Intracerebral Arterioles Extraluminal and Intraluminal Application. Circ Res 73, 
448–457. 
Nomoto S, Miyake M, Ohta M, Funakoshi A & Miyasaka K (1999). Impaired learning 
and memory in OLETF rats without cholecystokinin (CCK)-A receptor. Physiol 
Behav 66, 869–872. 
Nöth U, Kotajima F, Delchmann R, Turner R & Corfield DR (2008). Mapping of the 
cerebral vascular response to hypoxia and hypercapnia using quantutative perfusion 
MRI at 3T. NMR Biomed 21, 464–472. 
Ohta M, Toyama K, Gutterman DD, Campbell WB, Lemaître V, Teraoka R & Miura H 
(2013). Ecto-5′-nucleotidase, CD73, is an endothelium-derived hyperpolarizing 
factor synthase. Arterioscler Thromb Vasc Biol 33, 629–636. 
Olver TD, Mcdonald MW, Klakotskaia D, Richardson RA, Jasperse JL, Melling CWJ, 
Schachtman TR, Yang HT, Emter CA & Laughlin MH (2017). A chronic physical 
activity treatment in obese rats normalizes the contributions of ET-1 and NO to 
insulin-mediated posterior cerebral artery vasodilation. J Appl Physiol 122, 1040–
1050. 
Osol G, Brekke JF, Mcelroy-Yaggy K & Gokina NI (2002). Myogenic tone, reactivity, 
and forced dilatation: a three-phase model of in vitro arterial myogenic behavior. Am 
J Physiol Hear Circ Physiol 283, H2260–H2267. 
Paisansathan C, Xu H, Vetri F, Hernandez M & Pelligrino DA (2010). Interactions 
between adenosine and K + channel-related pathways in the coupling of 
somatosensory activation and pial arteriolar dilation. Am J Physiol - Hear Circ 
75 
75 
Physiol 299, 2009–2017. 
Paterno R, Heistad DD & Faraci FM (2000). Potassium channels modulate cerebral 
autoregulation during acute hypertension. Am J Physiol Hear Physiol 278, H2003–
H2007. 
Patrono C (2016). Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic 
and clinical perspective. Br J Clin Pharmacol957–964. 
Payne RA, Wilkinson IB & Webb DJ (2010). Arterial stiffness and hypertension: 
Emerging concepts. Hypertension 55, 9–14. 
Peterson EC, Wang Z & Britz G (2011). Regulation of cerebral blood flow. Int J Vasc 
Med 2011, 8. 
Phillips SA, Sylvester FA & Frisbee JC (2005). Oxidant stress and constrictor reactivity 
impair cerebral artery dilation in obese Zucker rats. Am J Physiol Regul Integr Comp 
Physiol 288, R522–R530. 
Piechnik SK, Chiarelli PA & Jezzard P (2008). Modelling vascular reactivity to 
investigate the basis of the relationship between cerebral blood volume and flow 
under CO 2 manipulation. Neuroimage 39, 107–118. 
Pires PW, Dams Ramos CM, Matin N & Dorrance AM (2013). The effects of 
hypertension on the cerebral circulation. Am J Physiol Hear Circ Physiol 304, 
H1598–H1614. 
Prentice DJ & Hourani SMO (2000). Characterisation of adenosine receptors mediating 
relaxation in hamster isolated aorta. Naunyn Schmiedebergs Arch Pharmacol 362, 
427–434. 
Ramkumar V, Hallam DM & Nie Z (2001). Adenosine, Oxidative Stress and 
Cytoprotection. Jpn J Pharmacol 86, 265–274. 
Reich T & Rusinek H (1989). Cerebral Cortical and White Matter Reactivity to Carbon 
Dioxide. Stroke 20, 453–457. 
Rogers J, Churilov L, Hannan AJ & Renoir T (2017). Search strategy selection in the 
Morris water maze indicates allocentric map formation during learning that 
underpins spatial memory formation. Neurobiol Learn Mem 139, 37–49. 
Roman R & Dokkum R (2014). Commentary on the Special Issue on the Impact of 
Myogenic Tone in Health and Disease. Curr Vasc Pharmacol 12, 779–780. 
Rosenberg GA (2009). Inflammation and White Matter Damage in Vascular Cognitive 
Impairment. Stroke 40, S20–S23. 
Sachidanandam K, Hutchinson JR, Elgebaly MM, Mezzetti EM, Dorrance AM, Motamed 
K & Ergul A (2009a). Glycemic control prevents microvascular remodeling and 
increased tone in Type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr 
Comp Physiol 296, 952–959. 
Sachidanandam K, Hutchinson JR, Elgebaly MM, Mezzetti EM, Dorrance AM, Motamed 
K & Ergul A (2009b). Glycemic control prevents microvascular remodeling and 
increased tone in Type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr 
76 
76 
Comp Physiol 296, 952–959. 
Sato A, Sakuma I & Gutterman DD (2003). Mechanism of dilation to reactive oxygen 
species in human coronary arterioles. Am J Physiol - Hear Circ Physiol 285, 2345–
2354. 
Schubert R, Kalentchuk VU & Krien U (2002). Rho kinase inhibition partly weakens 
myogenic reactivity in rat small arteries by changing calcium sensitivity. Am J 
Physiol Hear Circ Physiol 283, H2288–H2295. 
Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang M Il, Yim HW, 
Yoon KH & Son HY (2013). Metabolic syndrome as a predictor of type 2 diabetes, 
and its clinical interpretations and usefulness. J Diabetes Investig 4, 334–343. 
Smith BA, Clayton EW & Robertson D (2011). Experimental Arrest of Cerebral Blood 
Flow in Human Subjects: the Red Wing studies revisited. Perspect Biol Med; DOI: 
10.1353/pbm.2011.0018. 
Smith EE (2017). Clinical presentations and epidemiology of vascular dementia. Clin Sci 
131, 1059–1068. 
Sofroniew M V. & Vinters H V. (2010). Astrocytes: Biology and pathology. Acta 
Neuropathol 119, 7–35. 
Sohn HY, Krotz F, Gloe T, Keller M, Theisen K, Klauss V & Pohl U (2003). Differential 
regulation of xanthine and NAD(P)H oxidase by hypoxia in human umbilical vein 
endothelial cells. Role of nitric oxide and adenosine. Cardiovasc Res 58, 638–646. 
Sylvester FA, Stepp DW, Frisbee JC & Lombard JH (2002). High-salt diet depresses 
acetylcholine reactivity proximal to NOS activation in cerebral arteries. Am J 
Physiol Heart Circ Physiol 283, H353-63. 
Tabrizchi R & Bedi S (2001). Pharmacology of adenosine receptors in the vasculature. 
Pharmacol Ther 91, 133–147. 
Thorin-Trescases N & Bevan JA (1998). High Levels of Myogenic Tone Antagonize the 
Dilator Response to Flow of Small Rabbit Cerebral Arteries. Stroke 29, 1194–1201. 
Tilo G, Susanne F & Garret AF (2006). Biological basis for the cardiovascular 
consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin 
Invest 116, 4–15. 
Toblli JE, Cao G, DeRosa G, Di Gennaro F & Forcada P (2004). Angiotensin-Converting 
enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J 
Hypertens 17, 172–180. 
Tsai C-K, Kao T-W, Lee J-T, Wu C-J, Hueng D-Y, Liang C-S, Wang G-C, Yang F-C & 
Chen W-L (2016). Increased risk of cognitive impairment in patients with 
components of metabolic syndrome. Medicine (Baltimore) 95, e4791. 
Ungvari Z, Pacher P, Kecskemeti V, Papp G, Szollár L & Koller A (1999). Increased 
myogenic tone in skeletal muscle arterioles of diabetic rats. Possible role of 
increased activity of smooth muscle Ca2+ channels and protein kinase C. 
Cardiovasc Res 43, 1018–1028. 
77 
77 
Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodríguez-Iturbe B & Natarajan R 
(2005). Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP 
kinase, and matrix expressions in obesity. Kidney Int; DOI: 10.1111/j.1523-
1755.2005.00750.x. 
Vorhees C V. & Williams MT (2014). Assessing spatial learning and memory in rodents. 
ILAR J 55, 310–332. 
Wang Y, Liu G, Hong D, Chen F, Ji X & Cao G (2016). White matter injury in ischemic 
stroke. Prog Neurobiol 141, 45–60. 
Von der Weid PY (2013). Lymphatic myogenic constriction - how lymphatic vessels 
pump lymph uphill. J Physiol 591, 391–392. 
Wendler O, Landwehr P, Bandner-Risch D, Georg T & Schäfers HJ (2001). 
Vasoreactivity of arterial grafts in the patient with diabetes mellitus: Investigations 
on internal thoracic artery and radial artery conduits. Eur J Cardio-thoracic Surg 20, 
305–311. 
Willie CK, Macleod DB, Shaw AD, Smith KJ, Tzeng YC, Eves ND, Ikeda K, Graham J, 
Lewis NC, Day TA & Ainslie PN (2012). Regional brain blood flow in man during 
acute changes in arterial blood gases. J Physiol 590, 3261–3275. 
Willie CK, Smith KJ, Day TA, Ray LA, Lewis NCS, Bakker A, Macleod DB & Ainslie 
PN (2014a). Regional cerebral blood flow in humans at high altitude: gradual ascent 
and 2 wk at 5,050 m. J Appl Physiol 116, 905–910. 
Willie CK, Tzeng Y-C, Fisher JA & Ainslie PN (2014b). Integrative regulation of human 
brain blood flow. J Physiol 592, 841–859. 
Wilson MH, Edsell ME, Davagnanam I, Hirani SP, Martin DS, Levett DZ, Thornton JS, 
Golay X, Strycharczuk L, Newman SP, Montgomery HE, Grocott MP & Imray CH 
(2011). Cerebral artery dilatation maintains cerebral oxygenation at extreme altitude 
and in acute hypoxia-an ultrasound and MRI study. J Cereb Blood Flow Metab 31, 
2019–2029. 
Winocur G & Gagnon S (1998). Glucose treatment attenuates spatial learning and 
memory deficits of aged rats on tests of hippocampal function. Neurobiol Aging 19, 
233–241. 
Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP & Mcewen 
BS (2005). Memory Impairment in Obese Zucker Rats: An Investigation of 
Cognitive Function in an Animal Model of Insulin Resistance and Obesity. Behav 
Neurosci 119, 1389–1395. 
de Wit C, Schäfer C, von Bismarck P, Bolz S-S & Pohl U (1997). Elevation of plasma 
viscosity induces sustained NO-mediated dilation in the hamster cremaster 
microcirculation in vivo. Pflugers Arch Eur J Physiol 434, 354–361. 
Yates KF, Sweat V, Yau PL, Turchiano MM & Convit A (2012). Impact of metabolic 
syndrome on cognition and brain: A selected review of the literature. Arterioscler 
Thromb Vasc Biol 32, 2060–2067. 
Yokota A, Gamoh S, Tanaka-Totoribe N, Shiba T, Kuwabara M, Nakamura E, Hayase T, 
78 
78 
Hisa H, Nakamura K & Yamamoto R (2016). Angiotensin II, as well as 5-
hydroxytriptamine, is a potent vasospasm inducer of saphenous vein graft for 
coronary artery bypass grafting in patients with diabetes mellitus. Biochem Biophys 
Reports 6, 82–87. 
Yu YN, Li M-L, Xu Y-Y, Meng Y, Trieu H, Villablanca JP, Gao S, Feng F, Liebeskind 
DS & Xu W-H (2018). Middle cerebral artery geometric features are associated with 
plaque distribution and stroke. Neurology 00, 1–10. 
 
79 
79 
Appendices 
Appendix 1: Normalization analysis: automatic selection from HKG Panel 
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Appendix 2: Genes over-expressed in OZR vs LZR 
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Appendix 3: Genes under-expressed in OZR vs LZR 
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Appendix 4: Curve fits used for vascular reactivity statistical comparison 
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Appendix 5: Animal Use Protocol 
PI :  Frisbee, Jefferson  
Protocol #  2017-029  
Status :   Approved (w/o Stipulation)  
Approved :  09/01/2017  
Expires :  09/01/2021  
Title :  Vascular Dysfunction with Elevated CVD Risk  
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Animal Use Protocol Overview 
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Animal Holding/Housing and Use Location Information 
Animal Holding within Extra Vivarial Spaces (EVSs) 
Acclimatization Period & Quarantine 
Veterinary Drugs 
Experimental Agents Information 
SOP List 
Procedures Checklist for Reporting and Training 
Procedures Narrative 
Procedural Consequences & Monitoring 
Endpoint Method Information 
Animal Numbers Requested 
Protocol Attachments 
Protocol Introduction 
The questions on this page activate specific sections within the AUP form. 
Note that species selection is part of this introductory page 
Does this AUP involve teaching? 
 Yes   No  
Is the animal work on this project shared by another Animal Care Committee? 
 Yes   No  
Will you be using hazards? 
 Yes   No  
Will live animals be moved outside of their housing facility? 
 Yes   No  
Will field studies be conducted? 
 Yes   No  
Add/Update/Remove Species Used on this Protocol 
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 Species Agents Drugs Restraint Breeding 
 
  Rat   Yes   Yes   No   No  
Animal Use Protocol Overview 
Animal Use Protocol Title 
 Vascular Dysfunction with Elevated CVD Risk  
Application Type. If this is a post-pilot project, please attach the Pilot Report to this section, 
below. 
New 
Provide Associated Previous Protocol Number 
Please provide a report detailing the previous AUP's use of Animals 
 Replacement:  rodent models of elevated CVD risk have long been considered to be the gold 
standard for biomedical research and represent the optimal species from the perspective of 
replacement.  There are no other "simpler" models that would be appropriate and there are no 
models or simulations that can be substituted appropriately.  
  
Reduction:  based on our extensive experience with these species and models, this is the minimum 
number of animal usage to satisfactorily address the hypotheses and aims of the project.  In fact, we 
have developed a "parallel use" infrastructure in the laboratory to get maximum possible information 
from any individual animal in an attempt to use as few animals as possible.  
  
Refinement:  all techniques are well established and the PI is considered to be expert in each of 
them.  There is no further refinement that is possible while still adequately addressing the 
experimental questions proposed.  
Using non-scientific language, please describe the project's purpose, expected benefit, and a brief 
summary of your work with the animal model(s). 
 Public health research has identified that the presence of chronic stress and clinical depression is a 
severe risk factor for poor health outcomes, particularly with regard to cardiovascular disease. For 
future treatment, it is important that we acquire an accurate understanding of how chronic 
stress/depression causes poor cardiovascular health. The most appropriate rodent model for the 
effects of chronic stress/depression is 'Unpredictable Chronic Mild Stress' (UCMS), as it causes the 
animals to show all of the major symptoms of human clinical depression. We will expose rats and 
mice to the UCMS protocol and will determine its impact on depressive symptom severity and on 
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vascular function (which is the start of overt cardiovascular disease). While the UCMS protocol is 
neither painful nor requires restraint, it is based on a chronic, unpredictable change in their 
environment to cause constant stress. This can include altering light/dark cycles, the temporary use 
of wet bedding, cage tilts, etc. Both genders will be used as female rodents appear to be better 
protected (versus males) from vascular problems despite greater susceptibility to the UCMS protocol. 
The reasons for this protection are unknown and require investigation. The major benefits from this 
research effort will be the determination of how chronic stress/depressive symptoms causes vascular 
problems (providing guidance for how we can prevent this) and why females are protected from 
vascular problems in a way that males are not (also providing insight for future treatments).  
  
It is important to emphasize that we are NOT measuring depression.  "Depression" is a clinical 
diagnosis that cannot be applied to animal research.  We are measuring "depressive symptoms" (as 
outlined above) as a model for the human condition.  We use the UCMS model as this has been 
highly effective in behavioral and metabolic research to mimic the human condition.  
  
Further, we are not measuring "cardiovascular disease", but are measuring vascular dysfunction as a 
contributing element for cardiovascular disease risk.  "CVD" is a clinical condition and should not be 
applied to animals.  Vascular dysfunction (measured as outlined in the proposal) is a contributing 
factor to CVD, but should not be considered as CVD itself  -it is a condition that increases the risk for 
developing the overt pathology.  
GLOSSARY OF TERMS - Identify each individual scientific term and abbreviation using CAPITAL 
LETTERS, and then briefly define each term to be referenced in any section of this protocol.  
e.g. ALLELE - The genetic variant of a gene responsible for the different traits of certain 
characteristics and genetic diseases. 
 UCMS - Unpredictable Chronic Mild Stress  
Here is the link to CCAC's Policy on Scientific Merit and Ethical Review of Animal-based Research: 
http://www.ccac.ca/Documents/Standards/Policies/Scientific_merit_and_ethical_review_of_animal-
based_research.pdf 
(http://www.ccac.ca/Documents/Standards/Policies/Scientific_merit_and_ethical_review_of_animal-
based_research.pdf) Has the work outlined in this AUP received favourable scientific peer review? 
 Yes   No  
Do you wish to provide a funding peer review assessment, which may be considered in lieu of 
internal scientific peer review? If 'YES', please attach the funding assessment. 
 Yes   No  
If this is a RESEARCH AUP, please provide a list of one to three publications relevant to the work 
outlined in this AUP. 
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 1: Frisbee JC, Brooks SD, Stanley SC, d'Audiffret AC. An Unpredictable Chronic Mild Stress 
Protocol for Instigating Depressive Symptoms, Behavioral Changes and  Negative Health Outcomes 
in Rodents. J Vis Exp. 2015 Dec 2;(106). doi:  
10.3791/53109. PubMed PMID: 26650668.  
  
2: Stanley SC, Brooks SD, Butcher JT, d'Audiffret AC, Frisbee SJ, Frisbee JC. Protective effect of 
sex on chronic stress- and depressive behavior-induced vascular dysfunction in BALB/cJ mice. J 
Appl Physiol (1985). 2014 Nov 1;117(9):959-70. doi:  
10.1152/japplphysiol.00537.2014. Epub 2014 Aug 14. PubMed PMID: 25123201; PubMed Central 
PMCID: PMC4217050.  
  
3: d'Audiffret AC, Frisbee SJ, Stapleton PA, Goodwill AG, Isingrini E, Frisbee JC. Depressive 
behavior and vascular dysfunction: a link between clinical depression and vascular disease? J Appl 
Physiol (1985). 2010 May;108(5):1041-51.  doi: 10.1152/japplphysiol.01440.2009. Epub 2010 Feb 
18. PubMed PMID: 20167667; PubMed Central PMCID: PMC2867547.  
  
+++++++++++++++++++++++++++++  
The most concise outline would be provided in reference #1 above, a peer-reviewed publication with 
describes all stages to the protocol, the applications, rationale, objectives, etc. This reference is also 
associated with an on-line video that fully describes all aspects of the protocol. In brief:  
  
Background: the UCMS protocol is based in the recognition that many conditions of depression are 
associated with an environment of chronic stressors that cannot be accommodated or predicted. This 
results in behavioral, endocrine and inflammatory alterations to the animal that are highly comparable 
to that in the human subject. One of the health outcomes associated with chronic depressive states 
in both humans and animal subjects is elevated CVD risk and the development of states of overt 
CVD and vascular failure. One of the striking previous observations from our group is that female 
rodents, while suffering the depressive symptoms more severely, are protected from the 
vasculopathy as compared to responses in males. The purpose of the present studies is to determine 
the basis of this protection and how it can be used to improve future therapuetic approaches to 
treating health and disease.  
  
Rationale: Animal models experiencing UCMS develop depressive symptoms that are very similar to 
those determined in human subjects dealing with chronic depression in terms of their behavioral 
responses, alterations to endocrine profiles, systemic patterns of inflammatory biomarkers, etc. They 
also develop overt vasculopathies that are extremely consistent with those determined in human 
subjects as well, and demonstrate the sex-disparity that has been long identified through public 
health data. These experiments will use rat models (of both sexes) to determine the impact of chronic 
unresolvable stresses on both behavioral outcomes as well as vascular (dys)function.  
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Hypotheses: the broad hypotheses of the proposal state that, when exposed to chronic unresolvable 
stresses in their environment, female rats, although suffereing the behavioral responses more 
severely than males, exhibit a protection to the vascular structure and function, and show a superior 
maintenance of organ perfusion. This is based in the anti-oxidant and anti-inflammatory defense 
afforded by circulating sex hormones.  
  
Objectives: to determine the mechanistic bases of the sex-based protection in female as opposed to 
male rats subject to the unpredictable chronic mild stresses. This knowledge can then be used to 
better target interventional strategies to improve outcomes.  
  
Experimental Procedures: please see reference #1 (above) for a full presentation of all procedures.  
If this is a resarch AUP, attach an OUTLINE for scientific merit reviewers that provides sufficient 
information that another scientist working in the same field of study could effectively review this 
AUP's scientific merit, below. PIs may utilize whichever format best describes its scientific merit, 
e.g. background, rationale, hypothesis, objectives, experimental procedures 
Using only key words, specify the animal models and procedures described within this AUP. 
 fundamental research, chronic, rat, chronic stress, behavioral tests, UCMS - Unpredictable Chronic 
Mild Stress model, euthanasia  
Funding Source List 
 Fund Source Grant Title Funded? Grant Number Start Date
 Grant Holder 
 
  Internal Research Fund      Yes      /  /     
 
Funding Source Name 
Internal Research Fund 
Proposal Title 
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Is this award currently funded? 
 
Please provide the associated GRANT # 
Funding START date mm/dd/yy 
/ / 
PI on Grant (if different than PI on Protocol) 
Purpose of Animal Use 
Identify PRIMARY purpose of 
animal use 1-Fundamental 
Research 
Hazardous Materials 
Microorganism, Biological Agent or Hazardous Species Used? 
 Yes   No  
Institute Biosafety Committee # 
Recombinant DNA or Viral Vector Directly into Animals Used? 
 Yes   No  
Experimental Agents or Veterinary Drug Used? 
 Yes   No  
Hazardous Chemicals Registration # 
   
Nuclear Substance, Radiation, or Imaging Device Used? 
 Yes   No  
Radiation Permit # 
Animal Movement Outside of Animal Facilities 
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Will live animals move to or from laboratory animal facilities or external sites? 
 Yes   No  
Will live animals leave the laboratory animal facility? 
 Yes   No  
Per area outside of Animal Facility, list the room #, the specific procedures to be performed per 
room, and justify why these procedures cannot be performed within an Animal Facility. 
 Animals will be aged/exposed to the UCMS procedures in the institutional vivarium.  They will be 
removed from the vivarium ONLY for terminal usage as outlined in subsequent sections.  This 
movement will be from the vivarium to the PI laboratory (MSB 496) and animals will not be returned 
to the vivarium.  
Will either CW-443 Rodent Transport Containment Level 1, or CW-444 Non-Rodent Animal 
Transport be followed? 
 Yes   No  
Outline the method(s) used to transport animals between sites: Detail in chronological order the 
transfer route, including all Citywide 'Source' and 'Destination' sites, transport duration and 
frequency, and animal containment used. 
   
Animal Groups and Experimental Timelines Overview 
'C', 'D' and 'E'-level AUPs 
Using simple diagrams the following must be attached: 
 Animal Groups - names the animal groups (with unique identifiers) as well as the number of 
animals requested 
and 
 Experimental Timelines - names, in chronological order, ALL procedures that animals 
undergo (note that the description of each of these procedures is detailed in the Procedure 
Narrative section of the AUP   
  
'B'-level AUPs  
Attach Animals Groups and Experimental Timeline diagrams as described above 
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Attach a document that describes the same information in paragraph format.  
  
In the textbox below, please list file names of the most recent attachments 
 See attached 08.24.17  
Please attach your Groups and Timelines documents above. 
Rat Tissue Collection 
Will live animals be used in this study? 
Yes 
Will this species be used exclusively for tissue collection? 
 Yes   No  
Justification for Choice of Species 
Justify the choice of 
species by stating why 
a) this is the most 
appropriate species, 
and 
b) a species lower on the phylogenic scale is not appropriate. 
 This model calls of chronic stress and CVD in rats. While rats and mice can be used in the UCMS 
protocol, rat models are well established and allow for a more sophisticated physiological and 
pharmacological interrogation than is possible for mice, with the added benefit that the study of non-
atherosclerotic peripheral vascular disease is much more robust in rats than in mice. Additionally, the 
Obese Zucker rat strain is a well-established model of metabolic syndrome to the Lean Zucker 
background, allowing for the investigation of comorbid CVD on the effects of the stress protocol, 
stroke outcomes and efficacy of treatments.  
the 3Rs: Replace, Reduce, Refine 
The Three Rs concept originated from the scientific community and is a widely accepted 
cornerstone of policies on animal-based science around the world. 
Ethical animal use requires consideration of animal welfare needs http://3rs.ccac.ca 
(http://3rs.ccac.ca) 
Prior to any animal-based science, the 3 Rs should be considered. 
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Replacement refers to methods which avoid or replace the use of animals in an area where animals 
would otherwise have been used 
Please show how you've considered the tenet of Replacement in your AUP. 
For more information, please see Western's Alternative Use Guide 
(https://guides.lib.uwo.ca/animalalternatives). 
Replacement Consideration 
 Replacement:  rodent models of elevated CVD risk have long been considered to be the gold 
standard for biomedical research and represent the optimal species from the perspective of 
replacement.  There are no other "simpler" models that would be appropriate and there are no 
models or simulations that can be substituted appropriately.  
  
Reduction refers to any strategy that will result in fewer animals being used. 
Please show how you've considered the tenet of Reduction in your AUP. 
For more information, please see Western's Alternative Use Guide 
(https://guides.lib.uwo.ca/animalalternatives). 
Reduction Consideration 
 Reduction:  based on our extensive experience with these species and models, this is the minimum 
number of animal usage to satisfactorily address the hypotheses and aims of the project.  In fact, we 
have developed a "parallel use" infrastructure in the laboratory to get maximum possible information 
from any individual animal in an attempt to use as few animals as possible.  
Refinement refers to the modification of husbandry or experimental procedures to minimize pain 
and distress in your animals. 
Please show how you've considered the tenet of Refinement in your AUP. 
For more information, please see Western's Alternative Use Guide 
(https://guides.lib.uwo.ca/animalalternatives). 
Refinement Consideration 
 Refinement:  all techniques are well established and the PI is considered to be expert in each of 
them.  There is no further refinement that is possible while still adequately addressing the 
experimental questions proposed.  
Species Strains 
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 Species Strain Age/Weight Vendor Stock# 
 Sprague Dawley   7-20 Weeks   Envigo  
 ZDF-Leprfa (lean)   7-20 Weeks   Envigo  
 ZDF-Leprfa (obese)   7-20 Weeks   Envigo  
 ZUC-Lepr^fa (lean)   200-350g   Charles River or Envigo  
  ZUC-Lepr^fa (obese)   300-700g   Charles River or Envigo  
 
Strain Name 
Sprague Dawley 
Is this strain acquired commercially? 
 Yes   No  
Are the animals coming from a non-commercial source or another AUP? 
Provide 'supplier name' and stock #, if available 
Envigo 
Age or weight at procurement 
7-20 Weeks 
Provide phenotype detail for non-genetically altered strains 
   
Is this strain genetically altered? 
 Yes   No  
If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR STRAIN INFO 
URL. 
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE the Original 
Source of Animal(s) 
Describe the NATURE of the genetic modification in heterozygous and homozygous animals. 
Identify the SYSTEMS AFFECTED and SPECIAL CARE required. 
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Strain Name 
ZDF-Leprfa (lean) 
Is this strain acquired commercially? 
 Yes   No  
Are the animals coming from a non-commercial source or another AUP? 
Provide 'supplier name' and stock #, if available 
Envigo 
Age or weight at procurement 
7-20 Weeks 
Provide phenotype detail for non-genetically altered strains 
   
Is this strain genetically altered? 
 Yes   No  
If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR STRAIN INFO 
URL. 
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE the Original 
Source of Animal(s) 
Describe the NATURE of the genetic modification in heterozygous and homozygous animals. 
Identify the SYSTEMS AFFECTED and SPECIAL CARE required. 
   
 
Strain Name 
ZDF-Leprfa (obese) 
Is this strain acquired commercially? 
 Yes   No  
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Are the animals coming from a non-commercial source or another AUP? 
Provide 'supplier name' and stock #, if available 
Envigo 
Age or weight at procurement 
7-20 Weeks 
Provide phenotype detail for non-genetically altered strains 
   
Is this strain genetically altered? 
 Yes   No  
If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR STRAIN INFO 
URL. 
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE the Original 
Source of Animal(s) 
Describe the NATURE of the genetic modification in heterozygous and homozygous animals. 
Identify the SYSTEMS AFFECTED and SPECIAL CARE required. 
   
 
Strain Name 
ZUC-Lepr^fa (lean) 
Is this strain acquired commercially? 
 Yes   No  
Are the animals coming from a non-commercial source or another AUP? 
Provide 'supplier name' and stock #, if available 
Charles River or Envigo 
Age or weight at procurement 
200-350g 
Provide phenotype detail for non-genetically altered strains 
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 Fawn Hooded background, male and females, these are the healthy control for 
the obese Zucker rat. Is this strain genetically altered? 
 Yes   No  
If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR STRAIN INFO 
URL. 
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE the Original 
Source of Animal(s) 
Describe the NATURE of the genetic modification in heterozygous and homozygous animals. 
Identify the SYSTEMS AFFECTED and SPECIAL CARE required. 
   
 
Strain Name 
ZUC-Lepr^fa (obese) 
Is this strain acquired commercially? 
 Yes   No  
Are the animals coming from a non-commercial source or another AUP? 
Provide 'supplier name' and stock #, if available 
Charles River or Envigo 
Age or weight at procurement 
300-700g 
Provide phenotype detail for non-genetically altered strains 
 This is the rat model for metabolic disease that we need to use moving forward.  Severe leptin 
resistance, steady development of obesity, insulin resistance (leading to T2DM), dyslipidemia and 
hypertension.  Based on the Fawn Hooded parental strain, the OZR still has the similar coat 
appearance.  We need both males and females over the course of the protocol.  Thanks.  
Is this strain genetically altered? 
 Yes   No  
If Genetically Altered Animals are COMMERCIALLY AVAILABLE, insert VENDOR STRAIN INFO 
URL. 
If Genetically Altered Animals are from a NON-COMMERCIAL SOURCE, PROVIDE the Original 
Source of Animal(s) 
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Describe the NATURE of the genetic modification in heterozygous and homozygous animals. 
Identify the SYSTEMS AFFECTED and SPECIAL CARE required. 
   
Animal Transfers 
Will animals originate from a DIFFERENT CITYWIDE PROTOCOL NUMBER? 
 Yes   No  
Are any animals being transferred from another AUP that have previous use? 
 Yes   No  
List AUP number and PI name from which animals will be transferred 
   
Describe the previous use of animals sourced from different citywide AUPs. 
   
Environmental Enrichment 
Will all animals be group housed? 
 Yes   No  
Justify why group housing is not planned and specify which experimental animals will be singely 
housed 
 Animals in the UCMS protocol must be single housed to prevent social support (which would defeat 
the purpose of the protocol).  This is the only modification necessary.  
May Animal Care staff provide ENVIRONMENTAL ENRICHMENT to all animals of this species, as 
per its facility-specific Environmental Enrichment SOPs? 
 Yes   No  
May FOOD TREATS be given to all animals of this species by animal care staff as per its facility-
specific Environmental Enrichment SOPs? 
 Yes   No  
Explain why additional enrichment and/or food treats may not be provided by Animal Care staff 
 This protocol requires chronic stress to be successful.  Food treats and environmental enrichment 
undermine this for the UCMS animals.  
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Will any animals of this species undergo fasting at any point in the project? 
 Yes   No  
Provide justification and duration of fasting. 
 Simple overnight fast prior to final usage to ensure data quality and to consistently assess endocrine 
status at time of tissue harvest.  
  
Trainees from the PIs laboratory will remove food at 8PM on the day prior to final animal usage.  
Rats will still retain access to water during this period, and yes - only bedding and water will be 
provided for the 12 hour period prior to usage. If this species has other specialized caging, 
dietary or environmental requirements that you wish the animal facility manager(s) to be 
aware of, please identify them here. 
 .  
Animal Holding/Housing and Use Location Information 
 Location/Building Room Type 
 
 Location/Building Room Type 
 *West Valley Animal Care Facility   *Housing Room   HOUSING  
 MEDICAL SCIENCES - OTHER   498   USE  
ANIMAL LOCATION 
*Health Sciences Animal Care Facility   *Housing 
Room 
Location Type 
HOUSING 
Identify the Procedure Location PURPOSE 
  
 *Health Sciences Animal Care Facility    *Housing Room    HOUSING   
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ANIMAL LOCATION 
*West Valley Animal Care Facility   *Housing Room 
Location Type 
HOUSING 
Identify the Procedure Location PURPOSE 
  
ANIMAL LOCATION 
MEDICAL SCIENCES - OTHER   498 
Location Type 
USE 
Identify the Procedure Location PURPOSE 
Anesthesia;Blood Collection;Euthanasia;Non-recovery Surgery 
Animal Holding within Extra Vivarial Spaces (EVSs) 
Will animals be held outside a laboratory animal facility for more than 12 hours and/or overnight? 
 Yes   No  
Per EVS locattion, list the room #, the specific procedures to be performed per room, and justify 
why animals must be held outside an Animal Facility for more than 12 hours and/or overnight. 
   
Per area, provide the maximum duration and timeframe that live animals will be held, and estimate 
the number of cohorts anticipated per year. 
   
Acclimatization Period & Quarantine 
Will this species be held for the species-appropriate holding period prior to any form of USE, as 
per SOP 310? 
 Yes   No  
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Provide Justification for this exemption 
   
Will this species require quarantine? 
 Yes   No  
If quarantine requirements differ from the animal holding/housing facility's standard practice, 
please outline the requested QUARANTINE DETAIL. 
   
Veterinary Drugs 
Add all veterinary drugs to be used for therapeutic purposes in this AUP - planned veterinary 
treatments, e.g. anaesthesia, analgesia, post-op care, and euthanasia. 
Note: Agents, materials, drugs and devices that are included in the experimental design of this AUP 
for this species should be added to the next Experimental Agents web page. 
Drug Dosage 
Route of 
Administration 
Frequency 
Justification 
of 
Divergence 
Pharma 
Grade 
 
Alphachloralose  
               
 Pentobarbital  
Sodium  
 40-60 
mg/kg  
 IP;IV  
 1X initial anesthesia 
(IP), +10 mg/kg (IV or IP) 
as needed   No 
divergence   Yes  
  Urethane                 
 
Drug Generic Name 
Alpha-choloralose  
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Drug Type 
Drug Dosage 
Frequency of Administration 
Route of Administration 
Please justify any divergence from the standard dosage 
   
Is this a Pharmaceutical Grade Drug? 
 Yes   No  
Please justify the use of this drug and indicate how it is sterilized or determined to be pathogen-
free. 
   
 
Drug Generic Name 
Pentobarbital Sodium 
Drug Type 
Drug Dosage 
40-60 mg/kg 
Frequency of Administration 
1X initial anesthesia (IP), +10 mg/kg (IV or IP) as needed 
Route of Administration 
IP;IV 
Please justify any divergence from the standard dosage 
 No divergence  
Is this a Pharmaceutical Grade Drug? 
 Yes   No  
Please justify the use of this drug and indicate how it is sterilized or determined to be pathogen-
free. 
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Drug Generic Name 
Urethane 
Drug Type 
Anesthetic, Sedative 
Drug Dosage 
Frequency of Administration 
Route of Administration 
Please justify any divergence from the standard dosage 
   
Is this a Pharmaceutical Grade Drug? 
 Yes   No  
Please justify the use of this drug and indicate how it is sterilized or determined to be pathogen-
free. 
   
Experimental Agents Information 
Select all agents, materials, drugs and devices that are included in the experimental design of this 
AUP for this species. 
Note: Veterinary drugs to be used for planned veterinary treatments, e.g. anaesthesia, analgesia, 
post-op care, and euthanasia, are to be included on the previous Veterinary Drugs web page. 
Agent Name 
Common 
/trade name Class Category 
Pharma 
Grade 
 Urethane (ethyl 
Carbamate)   Urethane  
 Health Hazard (ghs) - 
Complete Safety Form   Chemical   Yes  
 Alpha-chloralose   Chloralose   Exempt From Safety Review   Chemical   Yes  
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 Pentobarbital 
Sodium  
 Euthanyl  
 Controlled Drug, Exempt From 
Safety Review  
  
Pharmaceutical  
 Yes  
Agent 
Urethane 
(ethyl 
Carbamate) 
Category 
Chemical 
Common /trade name 
Urethane 
Concentration of agent 
Dose administered 
750mg/kg 
Volume administered  
As per animal weight 
Route of Administration 
IP 
Other Route of Administration 
Frequency of administration 
Once, only used for 
terminal experiments 
Will this agent be 
modified? 
 Yes   No  
Please list all modifications to the agent 
   
Is this a Pharmaceutical Grade Agent? 
 Yes   No  
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Please justify the use of this agent and indicate how it is sterilized or determined to be pathogen-
free. 
   
Agent 
Alpha-chloralose 
Category 
Chemical 
Common /trade name 
Chloralose 
Concentration of agent 
Dose administered 
80 mg/kg 
Volume administered 
As per animal weight 
Route of Administration 
IP 
Frequency of administration  
Once -used for terminal experiments only 
Will this agent be 
modified? 
 Yes   No  
Please list all modifications to the agent 
   
Is this a Pharmaceutical Grade Agent? 
 Yes   No  
Please justify the use of this agent and indicate how it is sterilized or determined to be pathogen-
free. 
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Agent 
Pentobarbital Sodium 
Category 
Pharmaceutical 
Common /trade name 
Euthanyl 
Concentration of agent 
240 mg/ml 
Dose administered 
50 mg/kg 
Volume administered 
50 mg/kg concentration (between 0.3-0.7 ml total volume) 
Route of Administration 
IP;IV 
Other Route of Administration 
Frequency of administration 
1X initially (50 mg/ kg, IP), + 
10mg/kg IP or IV as needed Will this 
agent be modified? 
 Yes   No  
Please list all modifications to the agent 
   
Is this a Pharmaceutical Grade Agent? 
 Yes   No  
Please justify the use of this agent and indicate how it is sterilized or determined to be pathogen-
free. 
   
Please attach all requested documentation, as applicable, including:  
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Hazardous Materials Safety Questions Documents - If the classification of the agent selected requires 
it, please fill out and append the appropriate safety review sheet: 
Biological (http://www.uwo.ca/animal-research/doc/biological-questions.doc) 
Chemical/Pharmaceutical (http://www.uwo.ca/animal-research/doc/chem-pharm-questions.doc) 
Imaging & Laser (http://www.uwo.ca/animal-research/doc/imaging-laser-questions.doc) 
Nuclear/Radiation (http://www.uwo.ca/animal-research/doc/nuclear-radiation-questions.doc) 
Material Safety Data Sheet (MSDS) or Equivalent - Occupational Health & Safety requires that you 
attach the current MSDS for each newly added agent as this is an essential element of safety review. 
SOP List 
Add all Standard Operating Procedures that will be followed within this AUP. 
Go to the ACVS SOPs web page for SOP details - http://uwo.ca/animal-research/sops/index.html 
(http://uwo.ca/animalresearch/sops/index.html)  
 SOP Name Divergences 
 
  Cln-310 - Holding Period Post-admission     
 
Select an SOP 
Cln-310 - Holding 
Period Post-admission 
Are you following 
the SOP exactly? 
 Yes   No  
If you are not following the SOP exactly, please list and justify all divergences from the SOP 
   
Procedures Checklist for Reporting and Training 
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Use the checklist below to identify all AUP elements to be used with this species.  If none of the 
listed AUP elements pertain to this species, select *Not Applicable. 
Entries selected here will be linked to other AUP pages, including Personnel Training Requirements 
and the eSirius Training Module where animal user training records are maintained.  Therefore, 
please ensure that this list is complete. Procedure Name 
 
 06. Injections - Ip  
 
 17. Anesthetics - Injectable  
 
 20. Surgery - Non-recovery  
 
 I. Behavioral Testing  
Procedures Narrative 
In view of the live animal activities identified within this AUP and listed below, provide a concise 
description of the procedural events identified within the Groups and Timelines page associated 
with this specific species.  
The intent is to name and briefly describe the procedural events and associate them with each 
experimental group within this species. 
Specific detail pertaining to drug dosage, monitoring, euthanasia/endpoint method, breeding, and 
physical restraint methods have been captured within other AUP sections, so they do not need to 
be described in detail here. 
 Species Description 
Use the following formatting method to complete each procedure listed within this section: 
1. Bold Font for Procedure Name - e.g. Anesthesia 
2. Italicized Font for Group Identifiers - e.g. Groups 1, 2, and 6 
110 
110 
3. Regular Font for Procedure Description - e.g. Animals will be placed in a clean cage for 
transport to the OR 
Please note that the AUP will be returned for updates if this section does not align with the above 
formatting method. 
Procedures Narrative 
Unpredictable Chronic Mild Stress Procedure 
UCMS 
Control animals will be maintained in their home cages at all times, while UCMS groups will be 
exposed to the series of challenges within that protocol. All stressors will be imposed during the 
working day and, unless specifically noted, will be terminated by 5PM. At that point, the animals will 
be returned to a normal home cage with fresh bedding overnight. The earliest a new stress will be 
applied is 8AM on the successive day. These stressors will be varied on a daily basis and will 
include: a. Damp bedding 10 oz. of water will be added to each standard cage for the next 3 hours. 
After this time, the wet bedding will be replaced with normal dry bedding until the stress protocol on 
the following day. This will use warm water (30 C) to minimize the potential for temperature 
problems. b. Water all bedding will removed and ~0.5 inches (rat) of water added to empty cage for 
the next 3 hours. To prevent the development of hypothermia, all water will be maintained at between 
30-35 degrees C and animals will be briefly dried with a towel prior to placement back in cages with 
normal dry bedding. c. Each cage tilted to 45 degrees with or without bedding for 3 hours, and will be 
locked in place with a block and clamps. At the conclusion of this step, normal bedding will be 
replaced and the cage restored to its normal orientation. d. Social stress each rat is switched (i.e., 
replaced) into a cage of a neighboring animal for 3 hours. As this step involves replacing the animals 
in a cage with animals from neighboring cages, the potential for fighting is not present. This does 
NOT involve adding an animal from one cage into a different cage with the original animal still 
present. Animals will be returned to new cages with clean dry bedding after the 3 hour period. e. No 
bedding lasting for 3 hours or, on two occasions each week, overnight. Immediately following the 3 
hour period or immediately following the overnight period (i.e., at 8AM), clean, dry bedding will be 
replaced into the cages. f. Alternating light/dark periods, lasting 30 minutes, for 8 hours, within a day. 
This will begin at 8AM during the day in question and terminate at 4PM on that same day, at which 
time the animal will be returned its normal light/dark cycle. g. Exposure to predator smells (e.g., tufts 
of fur, 10-20 ml urine from cats) added to the cage for 3 hours. Usually, this step is assisted by the 
veterinary/maintenance staff in the animal housing facility by a collection procedure from housed 
cats. At the conclusion of this exposure, fresh bedding will be replaced in the cage. If cat urine/fur are 
not available, this step in the UCMS protocol is generally eliminated. 
Anesthesia 
UCMS and Control (all animals) 
Acute anesthesia via intraperitoneal injection of urethane/chlorolose OR pentobarbital sodium.  
Animals will be anesthetized for no more than 15-20 minutes prior to surgical tissue recovery. No 
ventilator will be used for these procedures. ***while this is essentially a very deep anesthesia 
followed by tissue harvest, we have elected to consider this as non-survival surgery in order to 
ensure full compliance for ourselves and the institution. Animals are terminated within 15 minutes of 
full anesthesia. ***we have utilized nembutal previously for our work and this amendment is to 
provide us with the ability to use it in the future.  However, we request the flexibility of maintaining our 
use of urethane/chlorolose as well for novel collaborations here at Western.   
Tissue Recovery 
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UCMS and Control (all animals) 
While fully anesthetized, full tissue recovery will be performed. This will include blood, aorta and 
other vessels and heart, thus resulting in the death of the animal while deeply anesthetized. 
Behavioral Testing and Analyses 
UCMS and Control (all animals) 
On a weekly basis, all animals will undergo a depressive symptom severity screening . In this, 
established indices of depressive symptoms in rodents will be evaluated. These tests include: a. 
Coat Status: This evaluation is done in the home cage. This evaluation is done weekly throughout 
the duration of the UCMS protocol. The total cumulative score is computed by giving an individual 
score of 0 (clean) or 1 (dirty) to eight body parts (head, neck, dorsal coat, ventral coat, tail, forelimb, 
hind-limb, and genital region). b. Splash Test: This test is done on iso pads to prevent bedding from 
adhering to the animal. This test is used to evaluate acute grooming behavior, defined as cleaning of 
the fur by licking or scratching. A 10% sucrose solution is sprayed on the dorsal coat of each rat and 
grooming activity was recorded for five minutes. The viscosity of the sucrose solution will dirty the 
coat and induce grooming behavior, with depressive symptoms characterized by an increased 
latency (idle time between spray and initiation of grooming) and decreased frequency (number of 
times grooming a particular body part). A. Locomotor activity: Locomotor activity will be measured as 
an index of the degree of symptom severity by neurological impairment using an automated activity 
monitoring system (San Diego Instruments, San Diego, CA). The rats will be given 30 60 min to 
acclimate to the testing room before being habituated to the testing chambers for an additional 30 
min. Each testing chamber consists of two 16 16 photobeam arrays to detect movements of the 
animals. Ambulatory, fine, and rearing movements will be quantified to give an overall activity score. 
The animals will be returned to the testing chambers and their activity was quantified for the next 30 
min. B. Elevated-plus Maze: The elevated-plus maze is well accepted for assessing anxiety-like 
behavior of rats and we will use this assay as described in the literature. The plus-maze consists of 
two open arms (50 cm x 10 m) and two enclosed arms (50 cm x 10 cm) with 30-cm high walls. The 
four arms meet at a central platform (10 cm x 10 cm) that opens to all arms, forming a + shape. The 
entire apparatus will be elevated 60 cm above the floor and surrounded by a padded surface. The 
apparatus will be illuminated with a ceiling lamp placed 90100 cm above the maze. The rat will be 
placed on the central platform facing an open arm. The number of entries and time spent in each of 
the arms will be recorded over a period of 5 minutes. Following testing, the rat will be placed back 
into its original cage. 
  
  
  
  
Procedures 
  
Behaviour Testing – 
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The current tests (outlined aboved) are used for assessing indices of chronic stress and depressive 
symptoms.  While those are valuable, they really do not give much of an indication of cognitive 
impairments.  The new tests (Morris Water Maze and Set Shifting) that will be performed with Dr. 
Whitehead's assistance will provide for a more robust understanding of the cognitive impairments 
that accompany the development of the metabolic syndrome.  At present, we will only use these tests 
in control LZR and OZR (i.e., rats that have NOT undergone the UCMS procedures). 
MORRIS WATER MAZE: Rats will be trained to swim to a platform in the spatial learning/working 
memory version of the Morris Water Maze, consisting of 4 trials/day for 4 consecutive days. Rats will 
then be subjected to two 30s probe trials where the platform is removed to assess rats spatial 
reference memory. To complete the task rats are placed in a circular pool (146cm diameter, 58cm 
high) and trained to escape from the water by swimming to a hidden platform. The water is 
maintained at a temperature of 21 1 C. Rats are allowed to swim in search of the platform for 90s. If 
the rat is unable to locate the platform in that time, they are guided to the platform and allowed to 
remain on it for 15s or 30s before being removed from the pool. If rats are not immediately re-
introduced into the pool, they are dried off after each trial with a towel and then placed back in their 
cages and kept under a heat lamp to stay warm until their next trial (approximately 15-20 min). 
Following the final trial rats are toweled dry and kept in their cage under a heat lamp for 15 min 
before being returned to the animal housing facility. There is no food or weight restriction required for 
this test. 
SET SHIFTING – Rats will be placed into an operant chamber box and will be trained to press a level 
corresponding to a light.  A sucrose pellet will be released upon the correct choice.  Up to 160 trials 
will be performed for each rat.  A mild food restriction will be enacted to provide additional incentive 
to perform the task (please see food restriction details below). 
Food Restriction for Set Shifting Behaviour - 
Rats in both of these Animal Groups will be trained to perform an appetitive operant conditioning 
behavioural task which involves food pellet reinforcement. Thus, while housed in their home cage, 
these rats will be on a food-restricted diet as this is a well-established procedure to optimize 
behavioural performance. This food restriction involves a limited amount of food to be available to the 
animal throughout the day, instead of food being available for continuous consumption. To ensure 
that the animals remain healthy and that the food restriction is not excessive, at the end of each 
behavioural testing session (less than 2 hours per day), the animals will be weighed and provided 
with supplemental food to maintain body weight at greater than 85% of normal body weight (as per 
Principal Investigator’s recent publication, Schormans et al., Frontiers in Behavioral Neuroscience, 
2017).  Trainees will be informed that the goal is to maintain the food-restricted animals above this 
85% level (e.g., ideally >90%), as this degree of weight reduction is the endpoint weight that guides 
our early euthanasia.  Effort will be made to keep the rats at >90% of weight reduction as long as our 
outcomes (animals that are performing behavioral tasks) are achieved.  Rats are maintained on this 
food-restricted diet up to a maximum of 14 days. Trainees will account for weekly weight gain in the 
rats so that they do not rely on using a single weight (15% less of the pre procedure weight) as their 
target or maximum allowable weight loss.  Monitoring charts for the animals on food restriction 
include a column that addresses the "target weight". This is expected to change weekly as we know 
the animals will gain weight as they age.   To that end, growth charts from the animal supplier will be 
used to gauge specified weight range as well as the animal’s short term running average weight. 
Procedural Consequences & Monitoring 
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From both the project overview & detail perspectives, identify and describe specific procedural or 
other/combined elements of this AUP that may produce pain, distress, or impairment - and 
identify all possible consequences Behavioural, Physical, Biochemical, Physiological, and 
Reproductive - for this species. 
 The UCMS procedures, by definition, cause chronic stress to the animal.  These are not painful, 
damaging or cause any impairment, they simple are chronic stresses to the system.  The behavioral 
outcomes can include lack of movement, failure to groom, anhedonia, learned helplessness, among 
others.  There should be no physical consequences.  Biochemical and physiological consequences 
are consistent with chronic stress and metabolic disease and can include elevated cortisol, oxidant 
radicals, inflammatory biomarkers, etc.  Reproductive consequences are not relevant for this 
protocol.  
  
There may be a minor weight loss (or reduction to the rate of increase) for rats as a result of the food 
restriction prior to the behavioral testing.  This is not expected to result in a loss of more than 3-5% of 
animal mass (at the most) and is anticipated that it will most likely result in no change in mass over 
the week.  If weight loss (monitored daily) exceeds 5%, this will result in the immediate termination of 
the behavioral testing due to unanticipated impacts on behavioral, metabolic and cardiovascular 
outcomes.  
  
Modification March 2019 - Morris Water Maze and Set Shifting  
There will be no procedural consequences as a result of these tests, and they will not have any 
lasting impact on an animal prior to final usage  
Detail relief to be provided for each of the above-stated potential consequences, and, if relief is 
not planned, offer scientific justification for not doing so. 
 There is no relief provided to the UCMS animals during the protocol, as this inherently undermines 
the purpose of the procedures.  
  
As stated above, no relief is planned as impacts on weight are anticipated to be minimal, if present.  
However, if weight loss exceeds 5%, all procedures will be terminated and the animal will be returned 
to normal ad libitum diet.  
The CCAC and OMAFRA require that all AUPs include: 
a 'Monitoring Plan' to minimize animal pain, distress, or discomfort, and a plan for 'Early 
Euthanasia' for the purpose of emergency intervention in advance of the experimental 
endpoint. 
  
As per UCAC's Animal Care and Use Records Policy, http://uwo.ca/animal-
research/doc/ACU_Records.pdf (http://uwo.ca/animal-research/doc/ACU_Records.pdf) Animal  
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Records, e.g. scoring sheets, procedure logs, anaesthetic and surgery records (except those 
involved in Field Studies) must be kept with the animals at all times. 
  
Has a monitoring sheet used for determining interventions and early euthanasia endpoints 
been developed for this species, e.g. scoring sheets, anaesthetic record, surgery record. If 
YES, please attach the monitoring sheet(s) below.  
  
If NO, please complete the following checklist 
 Yes   No  
Weight -When checked, this indicates that weights will be recorded 
Food/Water Intake 
Behaviour 
Fecal/Urine Output 
Body Condition Score 
Appearance 
Other Monitoring 
Please Specify Other Monitoring Type. 
   
For every individual monitoring element checked above:  
Describe the frequency, Specify the intervention points including criteria for early euthanasia, 
Provide other relevant detail. If attached monitoring sheets capture this information, then indicate 
this here. 
 Daily, if non healing wounds and injuries are present (even after treatment) animals will be 
euthanized.  Body mass will be determined 3X/week, with appropriate end points.  Lethargy and 
deteriorating grooming behavior will be assessed regularly (daily), although this is a part of the 
UCMS outcomes so must be assessed appropriately All other aspects will not result in early 
euthanasia as these can be outcomes of the procedures.  
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If an unforeseen animal welfare condition arises, we will discuss appropriate options with the 
vivarium staff/veterinarian. Please attach your monitoring sheets. 
Endpoint Method Information 
Endpoint Method 
 
 Drug-Agent Overdose  
 
Endpoint Method 
Drug-Agent Overdose 
CCAC Classification 
Acceptable 
This method is conditionally acceptable. Please provide sufficient justification for using this 
method. Please note that conditionally acceptable methods may require additional training prior 
to use. 
   
Provide Additional experimental endpoint detail, as required 
 Animals will be given an acute overdose of the urethane/chloralose anesthetic followed by a bilateral 
pneumothoracotomy and destruction of the heart to ensure euthanasia.  
Provide endpoint detail for animals not euthanized 
   
For endpoint methods selected above that use drugs, please list them below, and include the 
dosage. 
 Drug Dosage 
 
 Drug Dosage 
 >200 mg/kg  
116 
116 
  Urethane   >1000 mg/kg  
Animal Numbers Requested 
With a view to the animal numbers disclosed on the Groups and Timelines web page, please 
provide your requested total four- and first-year animal numbers by Category of Invasiveness as 
well as justification for these numbers.  
  
Please consider the activities selected for this species in the list below with a view to their combined 
impact upon an animal.   
 Species Type Description 
Please select the top Category of Invasiveness for this species and, for AUPs containing breeding 
colonies, please separate these numbers into the 'Z' category. 
Categories of Invasiveness – Levels assigned to AUPs in accordance with CCAC policy. 
Experiments involving: 
B - Little or no discomfort or stress 
C - Minor stress or pain of short duration 
D - Moderate to severe distress or discomfort 
E - Procedures causing severe pain at or above the pain tolerance threshold of 
unanaesthetized conscious animals 
Z - Animals used for breeding purposes (internal letter designation to separate out 
breeding from research numbers - a CCAC requirement) For more detail go to the CCAC 
Website: 
http://www.ccac.ca/en_/standards/policies/policy-categories_of_invasiveness 
(http://www.ccac.ca/en_/standards/policies/policy-categories_of_invasiveness) 
 CCAC Category 4 YR # 1st YR # 
 B   0   
0  
 C   0   
0  
 D   320   
0  
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 E   0   
0  
  Z   0   0  
  
Justification for Number of Animals Requested 
 Sample size has been determined based on historical numbers and experience based on animal 
phenotype, specific physiological outcome, and differences in health and disease outcomes.  
Additional numbers are included to determine mechanistic underpinnings of physiological 
observations.  The numbers used are the minimum number required to provide for statistically 
validated outcomes.  
  
https://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/statisticalpowercalculators.aspx  
 These are determined based on two-tailed tests, with an alpha = 0.5, and 25%  
differences between groups.  
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